Document:

EX-10.18

 Exhibit 10.18 

LOAN AND SECURITY AGREEMENT 

THIS LOAN AND SECURITY AGREEMENT is made and dated as of March 25, 2009 and is entered into by and between DICERNA PHARMACEUTICALS, INC.,
a Delaware corporation, and each of its subsidiaries, (hereinafter collectively referred to as the “Borrower”), and HERCULES TECHNOLOGY II, L.P., a Delaware limited partnership (“Lender”). 

RECITALS 
 A. Borrower has
requested Lender to make available to Borrower a loan in an aggregate principal amount of up to Seven Million Dollars ($7,000,000) (the “Term Loan”); 

B. Lender is willing to make the Term Loan on the terms and conditions set forth in this Agreement. 

AGREEMENT 
 NOW,
THEREFORE, Borrower and Lender agree as follows: 
  

	SECTION 1.	DEFINITIONS AND RULES OF CONSTRUCTION 

 1.1 Unless otherwise defined herein, the
following capitalized terms shall have the following meanings: 
 “Account Control Agreement(s)” means any agreement entered into
by and among the Lender, Borrower and a third party Bank or other institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment Property and which grants Lender a perfected first
priority security interest in the subject account or accounts. 
 “ACH Authorization” means the ACH Debit Authorization Agreement
in substantially the form of Exhibit H. 
 “Advance(s)” means a Term Loan Advance. 

“Advance Date” means the funding date of any Advance. 

“Advance Request” means a request for an Advance submitted by Borrower to Lender in substantially the form of Exhibit A. 

“Agreement” means this Loan and Security Agreement, as amended from time to time. 

“Assignee” has the meaning given to it in Section 11.13. 

“Borrower Products” means all products, software, service offerings, technical data or technology currently being designed,
manufactured or sold by Borrower or which Borrower intends to sell, license, or distribute in the future including any products or service offerings under development, collectively, together with all products, software, service offerings, technical
data or technology that have been sold, licensed or distributed by Borrower since its incorporation. 

  
 1 

 “Cash” means all cash and liquid funds. 

“Change in Control” means any (i) reorganization, recapitalization, consolidation or merger (or similar transaction or series
of related transactions) of Borrower or any Subsidiary, sale or exchange of outstanding shares (or similar transaction or series of related transactions) of Borrower or any Subsidiary in which the holders of Borrower or Subsidiary’s outstanding
shares immediately before consummation of such transaction or series of related transactions do not, immediately after consummation of such transaction or series of related transactions, retain shares representing more than fifty percent (50%)
of the voting power of the surviving entity of such transaction or series of related transactions (or the parent of such surviving entity if such surviving entity is wholly owned by such parent), in each case without regard to whether Borrower or
Subsidiary is the surviving entity, or (ii) sale or issuance by Borrower of new shares of Preferred Stock of Borrower to investors, none of whom are current investors in Borrower, and such new shares of Preferred Stock are senior to all
existing Preferred Stock and Common Stock with respect to liquidation preferences, and the aggregate liquidation preference of the new shares of Preferred Stock is more than fifty percent (50%) of the aggregate liquidation preference of all
shares of Preferred Stock of the Company; provided, however, an Initial Public Offering shall not constitute a Change in Control. 

“Claims” has the meaning given to it in Section 11.10. 

“Closing Date” means the date of this Agreement. 

“Collateral” means the property described in Section 3. 

“Commitment Fee” means $20,000, which fee is due to Lender on the Closing Date, and shall be deemed fully earned on such date
regardless of the early termination of this Agreement. 
 “Confidential Information” has the meaning given to it in
Section 11.12. 
 “Contingent Obligation” means, as applied to any Person, any direct or indirect liability, contingent or
otherwise, of that Person with respect to (i) any indebtedness, lease, dividend, letter of credit or other obligation of another, including any such obligation directly or indirectly guaranteed, endorsed,
co-made or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit,
corporate credit cards or merchant services issued for the account of that Person; and (iii) all obligations arising under any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or
other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; provided, however, that the term “Contingent Obligation” shall not include endorsements for
collection or deposit in the ordinary course of business. The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent Obligation is
made or, if not stated or determinable, the maximum reasonably anticipated 

  
 2 

 
liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the obligations under the
guarantee or other support arrangement. 
 “Copyright License” means any written agreement granting any right to use any Copyright
or Copyright registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest. 

“Copyrights” means (i) all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any
State thereof, or of any other country; (ii) all registrations, applications and recordings in the United States Copyright Office or in any similar office or agency of the United States, of any State thereof, or of any other country;
(iii) all continuations, renewals or extensions thereof; and (iv) all registrations to be issued under any pending applications. 

“Deposit Accounts” means any “deposit accounts,” as such term is defined in the UCC, and includes any checking account,
savings account, or certificate of deposit. 
 “ERISA” is the Employee Retirement Income Security Act of 1974, and its
regulations. 
 “Event of Default” has the meaning given to it in Section 9. 

“Facility Charge” means $77,000. 

“Financial Statements” has the meaning given to it in Section 7.1. 

“GAAP” means generally accepted accounting principles in the United States of America, as in effect from time to time. 

“Indebtedness” means indebtedness in accordance with GAAP including (a) all indebtedness for borrowed money or the deferred
purchase price of property or services (excluding trade credit entered into in the ordinary course of business due within sixty (60) days), including reimbursement and other obligations with respect to surety bonds and letters of credit,
(b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations, and (d) all Contingent Obligations. 

“Initial Public Offering” means the first sale of the Borrower’s common stock in a firm commitment underwritten offering
pursuant to a registration statement under the Securities Act of 1933 filed with and declared effective by the Securities and Exchange Commission. 

“Insolvency Proceeding” is any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy
or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief. 

“Intellectual Property” means all of Borrower’s Copyrights; Trademarks; Patents; Licenses; trade secrets and inventions; mask
works; Borrower’s applications therefor and 

  
 3 

 
reissues, extensions, or renewals thereof; and Borrower’s goodwill associated with any of the foregoing, together with Borrower’s rights to sue for past, present and future infringement
of Intellectual Property and the goodwill associated therewith. 
 “Investment” means any beneficial ownership (including stock,
partnership or limited liability company interests) of or in any Person, or any loan, advance or capital contribution to any Person or the acquisition of all, or substantially all, of the assets of another Person. 

“Joinder Agreements” means for each Subsidiary, a completed and executed Joinder Agreement in substantially the form attached hereto
as Exhibit G. 
 “Lender” has the meaning given to it in the preamble to this Agreement. 

“Lender Expenses” are all actual and reasonable audit fees and expenses, costs, and expenses (including reasonable attorneys’
fees and expenses) for preparing, negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings) or otherwise incurred with respect to
Borrower in connection with this Agreement. 
 “License” means any Copyright License, Patent License, Trademark License or other
license of rights or interests. 
 “Lien” means any mortgage, deed of trust, pledge, hypothecation, assignment for security,
security interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, and any lease in the nature of
a security interest. 
 “Loan” means the Advances made under this Agreement. 

“Loan Documents” means this Agreement, the Notes, the ACH Authorization, the Account Control Agreements, the Joinder Agreements, all
UCC Financing Statements, and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby (other than the Warrant), as the same may from time to time be amended, modified, supplemented or restated.

 “Material Adverse Effect” means a material adverse effect upon: (i) the business, operations, properties, assets,
prospects or condition (financial or otherwise) of Borrower and its subsidiaries taken as a whole other than an effect in and of itself reasonably attributable to the failure of any nonclinical or clinical trial to demonstrate the desired safety or
efficacy of any biologic or drug where, Borrower’s lead investors provide such reasonable confirmation to Lender as Lender reasonably requests that they continue to support the Borrower; or (ii) the ability of Borrower to perform the
Secured Obligations in accordance with the terms of the Loan Documents, or the ability of Lender to enforce any of its rights or remedies with respect to the Secured Obligations; or (iii) the Collateral or Lender’s Liens on the Collateral
or the priority of such Liens, in each case, in the aggregate. 

  
 4 

 “Maximum Term Loan Amount” means Seven Million Dollars ($7,000,000). 

“Maximum Rate” shall have the meaning assigned to such term in Section 2.3. 

“Note(s)” means a Term Note. 

“Patent License” means any written agreement granting any right with respect to any invention on which a Patent is in existence or a
Patent application is pending, in which agreement Borrower now holds or hereafter acquires any interest. 
 “Patents” means
(a) all letters patent of, or rights corresponding thereto, in the United States or in any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United
States or any other country, including registrations, recordings and applications in the United Stated and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country; (b) all reissues,
continuations, continuations-in-part or extensions thereof; (c) all petty patents, divisionals, and patents or additions; and (d) all patents to be issued
under any such applications. 
 “Permitted Indebtedness” means: (i) Indebtedness of Borrower in favor of Lender arising under
this Agreement or any other Loan Document; (ii) Indebtedness existing on the Closing Date which is disclosed in Schedule 1A; (iii) (omitted intentionally); (iv) Indebtedness to trade creditors incurred in the ordinary course of
business, including Indebtedness incurred in the ordinary course of business with corporate credit cards; (v) Indebtedness that also constitutes a Permitted Investment; (vi) Subordinated Indebtedness; (vii) reimbursement obligations
in connection with letters of credit that are secured by cash or cash equivalents and issued on behalf of the Borrower or a Subsidiary thereof in an amount not to exceed $200,000 at any time outstanding, (viii) other Indebtedness in an amount
not to exceed $100,000 at any time outstanding, and (ix) extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified to impose materially more
burdensome terms upon Borrower or its Subsidiary, as the case may be. 
 “Permitted Investment” means: (i) Investments
existing on the Closing Date which are disclosed in Schedule 1 B; (ii) (a) marketable direct obligations issued or unconditionally guaranteed by the United States of America or any agency or any State thereof maturing within one year from
the date of acquisition thereof, (b) corporate bonds rated A or better by Standard & Poor’s Corporation or A-2 by Moody’s Investors Service and commercial paper maturing no more than
one year from the date of creation thereof and currently having a rating of at least A-2 or P-2 from either Standard & Poor’s Corporation or Moody’s
Investors Service, (c) certificates of deposit issued by any bank with assets of at least $500,000,000 maturing no more than one year from the date of investment therein, and (d) money market accounts; (iii) repurchases of stock from
former employees, directors, or consultants of Borrower under the terms of applicable repurchase agreements at the original issuance price of such securities in an aggregate amount not to exceed $300,000 in any fiscal year, provided that no Event of
Default has occurred, is continuing or would exist after giving effect to the repurchases; (iv) Investments accepted in connection with Permitted Transfers; (v) Investments (including debt obligations) received in connection with the
bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or 

  
 5 

 
suppliers arising in the ordinary course of Borrower’s business; (vi) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and
suppliers who are not affiliates, in the ordinary course of business, provided that this subparagraph (vi) shall not apply to Investments of Borrower in any Subsidiary; (vii) Investments consisting of loans not involving the net
transfer on a substantially contemporaneous basis of cash proceeds to employees, officers or directors relating to the purchase of capital stock of Borrower pursuant to employee stock purchase plans or other similar agreements approved by
Borrower’s Board of Directors; (viii) Investments consisting of travel advances in the ordinary course of business; (ix) Investments in newly-formed Subsidiaries organized in the United States,
provided that such Subsidiaries enter into a Joinder Agreement promptly after their formation by Borrower and execute such other documents as shall be reasonably requested by Lender; (x) Investments in subsidiaries organized outside of the
United States approved in advance in writing by Lender; (xi) joint ventures or strategic alliances in the ordinary course of Borrower’s business consisting of the nonexclusive licensing of technology, the development of technology or the
providing of technical support, provided that any cash Investments by Borrower do not exceed $250,000 in the aggregate in any fiscal year; and (xii) additional Investments that do not exceed $250,000 in the aggregate in any fiscal year. 

“Permitted Liens” means any and all of the following: (i) Liens in favor of Lender; (ii) Liens existing on the Closing
Date which are disclosed in Schedule 1 C; (iii) Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in good faith by appropriate proceedings; provided, that Borrower maintains
adequate reserves therefor in accordance with GAAP; (iv) Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other like Persons arising in the ordinary course of Borrower’s business
and imposed without action of such parties; provided, that the payment thereof is not yet required; (v) Liens arising from judgments, decrees or attachments in circumstances which do not constitute an Event of Default hereunder; (vi) the
following deposits, to the extent made in the ordinary course of business: deposits under worker’s compensation, unemployment insurance, social security and other similar laws, or to secure the performance of bids, tenders or contracts (other
than for the repayment of borrowed money) or to secure indemnity, performance or other similar bonds for the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure statutory obligations (other than
liens arising under ERISA or environmental liens) or surety or appeal bonds, or to secure indemnity, performance or other similar bonds; (vii) (omitted intentionally); (viii) Liens incurred in connection with Subordinated Indebtedness;
(ix) leasehold interests in leases or subleases and licenses granted in the ordinary course of business and not interfering in any material respect with the business of the licensor; (x) Liens in favor of customs and revenue authorities
arising as a matter of law to secure payment of custom duties that are promptly paid on or before the date they become due; (xi) Liens on insurance proceeds securing the payment of financed insurance premiums that are promptly paid on or before
the date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property or assets); (xii) statutory and common law rights of set-off and other similar
rights as to deposits of cash and securities in favor of banks, other depository institutions and brokerage firms; (xiii) easements, zoning restrictions,
rights-of-way and similar encumbrances on real property imposed by law or arising in the ordinary course of business so long as they do not materially impair the value
or marketability of the related property; (xiv) Liens on cash or cash equivalents securing obligations permitted under clause (vii) of the definition of Permitted Indebtedness; and 

  
 6 

 
(xv) Liens incurred in connection with the extension, renewal or refinancing of the indebtedness secured by Liens of the type described in clauses (i) through (xi) above; provided,
that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the original, principal amount of the indebtedness being extended, renewed or refinanced does not increase. 

“Permitted Transfers” means (i) sales of Inventory in the normal course of business,
(ii) non-exclusive licenses and similar arrangements for the use of Intellectual Property in the ordinary course of business and licenses that do not result in a legal transfer of title of the licensed
property but that may be exclusive in respects other than territory and that may be exclusive as to territory only as to discreet geographical areas outside of the United States in the ordinary course of business, (iii) dispositions of worn-out, obsolete or surplus Equipment at fair market value in the ordinary course of business, and (iv) other Transfers of assets having a fair market value of not more than $250,000 in the aggregate in any
fiscal year. 
 “Person” means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated
organization, association, corporation, limited liability company, institution, other entity or government. 
 “Preferred Stock”
means at any given time any equity security issued by Borrower that has any rights, preferences or privileges senior to Borrower’s common stock. 

“Prepayment Charge” shall have the meaning assigned to such term in Section 2.3. 

“Prime Rate” means the Prime Rate published in the Money Rates section of the Western Edition of The Wall Street Journal. 

“Receivables” means (i) all of Borrower’s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, letters
of credit, proceeds of any letter of credit, and Letter of Credit Rights, and (ii) all customer lists, software, and business records related thereto. 

“Secured Obligations” means Borrower’s obligations under this Agreement and any Loan Document, including any obligation to pay
any amount now owing or later arising. 
 “Subordinated Indebtedness” means Indebtedness subordinated to the Secured Obligations
in amounts and on terms and conditions satisfactory to Lender in its commercially reasonable discretion. 
 “Subsequent Financing”
means the first sale in a venture capital financing by Borrower of its equity or convertible debt securities (post Series A) that closes after the Closing Date in which Borrower receives gross proceeds of at least $5,000,000. 

“Subsidiary” means an entity, whether corporate, partnership, limited liability company, joint venture or otherwise, in which
Borrower owns or controls 50% or more of the outstanding voting securities, including each entity listed on Schedule 1 hereto. 

  
 7 

 “Term Loan Advance” means any Term Loan funds advanced under this Agreement. 

“Term Loan Interest Rate” means for any day, the greater of (i) 12.95% or (ii) 12.95% plus the Prime Rate minus 3.75%, not
to exceed 15.50%. 
 “Term Loan Maturity Date” means April 1, 2012. 

“Term Note” means a Promissory Note in substantially the form of Exhibit B. 

“Trademark License” means any written agreement granting any right to use any Trademark or Trademark registration, now owned or
hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest. 
 “Trademarks” means all of the
following property, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest: (a) all trademarks (registered, common law or otherwise), tradenames, (and all goodwill associated therewith),
including registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof, and
(b) all reissues, extensions or renewals thereof. 
 “UCC” means the Uniform Commercial Code as the same is, from time to
time, in effect in the State of California; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Lender’s Lien on any Collateral is
governed by the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other than the State of California, then the term “UCC” shall mean the Uniform Commercial Code as in effect, from time to time, in such
other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions. 

“Warrant” means the warrant entered into in connection with the Loan. 

Unless otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a “Section,” “subsection,”
“Exhibit,” “Annex,” or “Schedule” shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement. Unless otherwise specifically provided herein, any accounting term used in
this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in accordance with GAAP, consistently applied. Unless otherwise defined
herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC. 

  
 8 

	SECTION 2.	THE LOAN 

 2.1 Term Loan. 

(a) Advances. Subject to the terms and conditions of this Agreement, Lender will make, and Borrower agrees to draw, a Term Loan Advance of
$2,000,000 on the Closing Date. Beginning May 30, 2009, and continuing through June 30, 2009, Borrower may request additional Term Loan Advances in an aggregate amount up to $3,000,000 in minimum increments of $1,500,000. From
September 15, 2009 through September 30, 2009, Borrower may request one additional Term Loan Advance in an aggregate amount up to $2,000,000. The aggregate outstanding Term Loan Advances may be up to the Maximum Term Loan Amount. 

(b) Advance Request. To obtain a Term Loan Advance, Borrower shall complete, sign and deliver an Advance Request and Term Note to Lender.
Lender shall fund the Term Loan Advance in the manner requested by the Advance Request provided that each of the conditions precedent to such Term Loan Advance is satisfied as of the requested Advance Date. 

(c) Interest. The principal balance of each Term Loan Advance shall bear interest thereon from such Advance Date at the Term Loan Interest
Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed. The Term Loan Interest Rate will float and change on the day the Prime Rate changes from time to time. 

(d) Payment. Borrower will pay interest on each Term Loan Advance on the first day of each month, beginning the month after the Advance Date.
Borrower shall repay the aggregate Term Loan principal balance that is outstanding on October 31, 2009 in equal monthly installments of principal and interest beginning November 1, 2009 and continuing on the first business day of each
month thereafter through the Term Loan Maturity Date (for clarity, the principal and interest components of equal installments may vary if the Term Loan Interest Rate changes); provided however, that if (1) Borrower enters into a strategic
collaboration generating upfront proceeds of not less than $15,000,000 or closes the sale of its equity securities in a like amount; OR (2) Borrower completes animal studies of a first target that generate results satisfactory to Borrower and
Lender, then Borrower will begin repaying the aggregate Term Loan principal balance that is outstanding on January 31, 2010 beginning on February 1, 2010 and continuing on the first business day of each month thereafter through the Term
Loan Maturity Date. The entire Term Loan principal balance and all accrued but unpaid interest hereunder, shall be due and payable on Term Loan Maturity Date. Borrower shall make all payments under this Agreement without setoff, recoupment or
deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to the Borrower’s account as authorized on the ACH Authorization on each payment date of all periodic obligations payable to Lender under each Term Note
or Term Advance. On or about the Closing Date, Lender will provide an amortization schedule to Borrower showing the payments and respective due dates. Lender will provide a revised schedule after any changes to the Term Loan Interest Rate. 

(e) Maximum Interest. Notwithstanding any provision in this Agreement, the Notes, or any other Loan Document, it is the parties’ intent
not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court of competent jurisdiction shall deem applicable hereto (which under the laws of the State of California shall be deemed
to be the laws relating to permissible rates of interest on commercial loans) (the “Maximum Rate”). If a court of competent jurisdiction shall finally determine that Borrower has actually paid to Lender an amount of interest in excess of
the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the 

  
 9 

 
Maximum Rate, then such excess interest actually paid by Borrower shall be applied as follows: first, to the payment of principal outstanding on the Notes; second, after all principal is repaid,
to the payment of Lender’s accrued interest, costs, expenses, professional fees and any other Secured Obligations; and third, after all Secured Obligations are repaid, the excess (if any) shall be refunded to Borrower. 

2.2 Default Interest. In the event any payment is not paid on the scheduled payment date, an amount equal to five percent (5%) of the
past due amount shall be payable on notice and demand to Borrower. In addition, upon the occurrence and during the continuation of an Event of Default hereunder, all Secured Obligations, including principal, interest, compounded interest, and
professional fees, shall bear interest at a rate per annum equal to the rate set forth in Section 2.1(c), plus five percent (5%) per annum. In the event any interest is not paid on the due date hereunder, delinquent interest shall be added
to principal and shall bear interest on interest, compounded at the rate set forth in Section 2.1(c). 
 2.3 Prepayment. At its option
upon at least 7 business days prior notice to Lender, Borrower may prepay all, but not less than all, of the outstanding Advances by paying the entire principal balance, all accrued and unpaid interest, together with a prepayment charge equal to the
following percentage of the Advance amount being prepaid: if such Advance amounts are prepaid in any of the first twelve (12) months following the Closing Date, 3.0%; after twelve (12) months but prior to twenty four (24) months,
2.0%; and thereafter, 1.0% (each, a “Prepayment Charge”). Borrower agrees that the Prepayment Charge is a reasonable calculation of Lender’s lost profits in view of the difficulties and impracticality of determining actual damages
resulting from an early repayment of the Advances. Borrower shall prepay the outstanding amount of all principal and accrued and unpaid interest upon the earlier to occur of a Change in Control or within 90 days of the completion of an Initial
Public Offering in which Borrower receives net proceeds of $30,000,000 or less. 
 2.4 End of Term Charge. On the earliest to occur of
(i) the Term Loan Maturity Date, (ii) the date that Borrower prepays the outstanding Secured Obligations, or (iii) the date that the Secured Obligations become due and payable, Borrower shall pay Lender a charge of $136,500.
Notwithstanding the required payment date of such charge, it shall be deemed earned by Lender as of the Closing Date. 
  

	SECTION 3.	SECURITY INTEREST 

 3.1 As security for the prompt, complete and indefeasible
payment when due (whether on the payment dates or otherwise) of all the Secured Obligations, Borrower grants to Lender a security interest in all of Borrower’s personal property now owned or hereafter acquired, including the following
(collectively, the “Collateral”): (a) Receivables; (b) Equipment; (c) Fixtures; (d) General Intangibles (other than Intellectual Property); (e) Inventory; (f) Investment Property (but excluding thirty-five percent (35%) of the capital stock of any foreign Subsidiary that constitutes a Permitted Investment); (g) Deposit Accounts; (h) Cash; (i) Goods; and other tangible and intangible
personal property of Borrower whether now or hereafter owned or existing, leased, consigned by or to, or acquired by, Borrower and wherever located; and, to the extent not otherwise included, all Proceeds of each of the foregoing and all accessions
to, substitutions and replacements for, and rents, profits and products of each 

  
 10 

 
of the foregoing; provided, however, that the Collateral shall include all Accounts and General Intangibles that consist of rights to payment and proceeds from the sale, licensing or disposition
of all or any part, or rights in, the Intellectual Property (the “Rights to Payment”). Notwithstanding the foregoing, if a judicial authority (including a U.S. Bankruptcy Court) holds that a security interest in the underlying Intellectual
Property is necessary to have a security interest in the Rights to Payment, then the Collateral shall automatically, and effective as of the date of this Agreement, include the Intellectual Property to the extent necessary to permit perfection of
Lender’s security interest in the Rights to Payment. 
  

	SECTION 4.	CONDITIONS PRECEDENT TO LOAN 

 The obligations of Lender to make the Loan
hereunder are subject to the satisfaction by Borrower of the following conditions: 
 4.1 Initial Advance. On or prior to the Closing Date,
Borrower shall have delivered to Lender the following: 
 (a) executed originals of the Loan Documents, Account Control Agreements, a legal
opinion of Borrower’s counsel, and all other documents and instruments reasonably required by Lender to effectuate the transactions contemplated hereby or to create and perfect the Liens of Lender with respect to all Collateral, in all cases in
form and substance reasonably acceptable to Lender; 
 (b) certified copy of resolutions of Borrower’s board of directors evidencing
approval of (i) the Loan and other transactions evidenced by the Loan Documents; and (ii) the Warrant and transactions evidenced thereby; 

(c) certified copies of the Certificate of Incorporation and the Bylaws, as amended through the Closing Date, of Borrower; 

(d) a certificate of good standing for Borrower from its state of incorporation and similar certificates from all other jurisdictions in which
it does business and where the failure to be qualified would have a Material Adverse Effect; 
 (e) payment of the Facility Charge and
reimbursement of Lender’s current expenses reimbursable pursuant to this Agreement, which amounts may be deducted from the initial Advance; and 

(f) such other documents as Lender may reasonably request. 

4.2 All Advances. On each Advance Date: 

(a) Lender shall have received (i) an Advance Request and a Note for the relevant Advance as required by Section 2.1(b), each duly
executed by Borrower’s Chief Executive Officer or Chief Financial Officer, and (ii) any other documents Lender may reasonably request. 

  
 11 

 (b) The representations and warranties set forth in this Agreement and in Section 5 and in
the Warrant shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date.

 (c) Borrower shall be in compliance with all the material terms and provisions set forth herein and in each other Loan Document on its
part to be observed or performed, and at the time of and immediately after such Advance no Event of Default shall have occurred and be continuing. 

(d) Each Advance Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date as to the
matters specified in paragraphs (b) and (c) of this Section 4.2 and as to the matters set forth in the Advance Request. 

4.3 No Default. As of the Closing Date and each Advance Date, (i) no fact or condition exists that constitutes an Event of Default and
(ii) no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing. 
  

	SECTION 5.	REPRESENTATIONS AND WARRANTIES OF BORROWER 

 Borrower represents and warrants
that: 
 5.1 Corporate Status. Borrower is a corporation duly organized, legally existing and in good standing under the laws of the State
of Delaware, and is duly qualified as a foreign corporation in all jurisdictions in which the nature of its business or location of its properties require such qualifications and where the failure to be qualified could reasonably be expected to have
a Material Adverse Effect. Borrower’s present name, former names (if any), locations, place of formation, tax identification number, organizational identification number and other information are correctly set forth in Exhibit C, as may be
updated by Borrower in a written notice (including any Compliance Certificate) provided to Lender after the Closing Date. 
 5.2 Collateral.
Borrower owns, or has right to, the Collateral and the Intellectual Property, free of all Liens, except for Permitted Liens. Borrower has the power and authority to grant to Lender a Lien in the Collateral as security for the Secured Obligations.

 5.3 Consents. Borrower’s execution, delivery and performance of the Notes, this Agreement and all other Loan Documents, and
Borrower’s execution of the Warrant, (i) have been duly authorized by all necessary corporate action of Borrower, (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than Permitted Liens and the
Liens created by this Agreement and the other Loan Documents, (iii) do not violate any provisions of Borrower’s Certificate or Articles of Incorporation (as applicable), bylaws, or any, law, regulation, order, injunction, judgment, decree
or writ to which Borrower is subject where such violation could reasonably be expected to have a Material Adverse Effect and (iv) except as described on Schedule 5.3, do not violate any contract or agreement where such violation could
reasonably be expected to have a Material Adverse Effect or require the consent or approval of any other Person (other than consents and approvals that have been obtained). The individual or individuals executing the Loan Documents and the Warrant
are duly authorized to do so. 

  
 12 

 5.4 Material Adverse Effect. No event that has had or could reasonably be expected to have a
Material Adverse Effect has occurred and is continuing. Borrower is not aware of any event likely to occur that is reasonably expected to result in a Material Adverse Effect. 

5.5 Actions Before Governmental Authorities. Except as described on Schedule 5.5, there are no actions, suits or proceedings at law or in
equity or by or before any governmental authority now pending or, to the knowledge of Borrower, threatened in writing against or affecting Borrower or its property. 

5.6 Laws. Borrower is not in violation of any law, rule or regulation, or in default with respect to any judgment, writ, injunction or decree
of any governmental authority, where such violation or default is reasonably expected to result in a Material Adverse Effect. Borrower is not in default under any agreement or instrument evidencing Indebtedness, or any other material agreement to
which it is a party or by which it is bound. 
 5.7 Information Correct and Current. No information, report, Advance Request, financial
statement, exhibit or schedule furnished, by or on behalf of Borrower to Lender in connection with any Loan Document or included therein or delivered pursuant thereto contained, contains any material misstatement of fact or omitted, omits or will
omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were, are or will be made, not misleading at the time such statement was made or deemed made. Additionally, any and all
financial or business projections provided by Borrower to Lender shall be (i) provided in good faith and based on the most current data and information available to Borrower, and (ii) the most current of such projections provided to
Borrower’s Board of Directors. 
 5.8 Tax Matters. Except as described on Schedule 5.8, (a) Borrower has filed all federal,
state and local tax returns that it is required to file, (b) Borrower has duly paid or fully reserved for all taxes or installments thereof (including any interest or penalties) as and when due, which have or may become due pursuant to such
returns, and (c) Borrower has paid or fully reserved for any tax assessment received by Borrower for the three (3) years preceding the Closing Date, if any (including any taxes being contested in good faith and by appropriate proceedings).

 5.9 Intellectual Property Claims. Borrower is the sole owner of, or otherwise has the right to use, the Intellectual Property. Each of
the material Copyrights, Trademarks and Patents is valid and enforceable, (ii) no material part of the Intellectual Property has been judged invalid or unenforceable, in whole or in part, and (iii) no written claim has been made to
Borrower that any material part of the Intellectual Property violates the rights of any third party. Exhibit D is a true, correct and complete list of each of Borrower’s Patents, registered Trademarks, registered Copyrights, and material
agreements under which Borrower licenses Intellectual Property from third parties (other than shrink-wrap software licenses), together with application or registration numbers, as applicable, owned by Borrower
or any Subsidiary, in each case as of the Closing Date. Borrower is not in material breach of, nor has Borrower failed to perform any material obligations under, any of the foregoing contracts, licenses or agreements and, to Borrower’s
knowledge, no third party to any such contract, license or agreement is in material breach thereof or has failed to perform any material obligations thereunder. 

  
 13 

 5.10 Intellectual Property. Borrower has, or in the case of any proposed business, will have, all
material rights with respect to Intellectual Property necessary in the operation or conduct of Borrower’s business as currently conducted and proposed to be conducted by Borrower. Without limiting the generality of the foregoing, and in the
case of Licenses, except for restrictions that are unenforceable under Division 9 of the UCC, Borrower has the right, to the extent required to operate Borrower’s business, to freely transfer, license or assign Intellectual Property without
condition, restriction or payment of any kind (other than license payments in the ordinary course of business) to any third party, and Borrower owns or has the right to use, pursuant to valid licenses, all software development tools, library
functions, compilers and all other third-party software and other items that are used in the design, development, promotion, sale, license, manufacture, import, export, use or distribution of Borrower
Products. 
 5.11 Borrower Products. No Intellectual Property owned by Borrower or Borrower Product has been or is subject to any actual or,
to the knowledge of Borrower, overtly threatened litigation, proceeding (including any proceeding in the United States Patent and Trademark Office or any corresponding foreign office or agency) or outstanding decree, order, judgment, settlement
agreement or stipulation that restricts in any manner Borrower’s use, transfer or licensing thereof or that may affect the validity, use or enforceability thereof. There is no decree, order, judgment, agreement, stipulation, arbitral award or
other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant licenses or ownership interest in any future Intellectual Property related to the operation or conduct of the business of Borrower or
Borrower Products. Borrower has not received any written notice or claim challenging Borrower’s ownership in any Intellectual Property (or written notice of any claim challenging the ownership in any licensed Intellectual Property of the owner
thereof) or suggesting that any third party has any claim of legal or beneficial ownership with respect thereto nor, to Borrower’s knowledge, is there a reasonable basis for any such claim. Neither Borrower’s use of its Intellectual
Property nor the production and sale of Borrower Products knowingly infringes the Intellectual Property or other rights of others. 
 5.12
Financial Accounts. Exhibit E, as may be updated by the Borrower in a written notice provided to Lender after the Closing Date, is a true, correct and complete list of (a) all banks and other financial institutions at which Borrower or any
Subsidiary maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding Investment Property, and such exhibit correctly identifies the name, address and telephone number of each bank or
other institution, the name in which the account is held, a description of the purpose of the account, and the complete account number therefor. 

5.13 Employee Loans. Borrower has no outstanding loans to any employee, officer or director of the Borrower nor has Borrower guaranteed the
payment of any loan made to an employee, officer or director of the Borrower by a third party. 
 5.14 Capitalization and Subsidiaries.
Borrower’s capitalization as of the Closing Date is set forth on Schedule 5.14 annexed hereto. Borrower does not own any stock, partnership interest or other securities of any Person, except for Permitted Investments. Attached as
Schedule 5.14, as may be updated by Borrower in a written notice provided after the Closing Date, is a true, correct and complete list of each Subsidiary. 

  
 14 

	SECTION 6.	INSURANCE; INDEMNIFICATION 

 6.1 Coverage. Borrower shall cause to be carried and
maintained commercial general liability insurance, on an occurrence form, against risks customarily insured against in Borrower’s line of business. Such risks shall include the risks of bodily injury, including death, property damage, personal
injury, advertising injury, and contractual liability per the terms of the indemnification agreement found in Section 6.3. Borrower must maintain a minimum of $2,000,000 of commercial general liability insurance for each occurrence. Borrower
has and agrees to maintain a minimum of $4,000,000 of directors and officers’ insurance for each occurrence and $4,000,000 in the aggregate. So long as there are any Secured Obligations outstanding, Borrower shall also cause to be carried and
maintained insurance upon the Collateral, insuring against all risks of physical loss or damage howsoever caused, in an amount not less than the full replacement cost of the Collateral, provided that such insurance may be subject to standard
exceptions and deductibles. Borrower shall also carry and maintain a fidelity insurance policy in an amount not less than $50,000. 
 6.2
Certificates. Borrower shall deliver to Lender certificates of insurance that evidence Borrower’s compliance with its insurance obligations in Section 6.1 and the obligations contained in this Section 6.2. Borrower’s insurance
certificate shall state Lender is an additional insured for commercial general liability, and a loss payee for all risk property damage insurance, subject to the insurer’s approval, a loss payee for fidelity insurance, and a loss payee for
property insurance and additional insured for liability insurance for any future insurance that Borrower may acquire from such insurer. Attached to the certificates of insurance will be additional insured endorsements for liability and lender’s
loss payable endorsements for all risk property damage insurance and fidelity. All certificates of insurance will provide for a minimum of thirty (30) days advance written notice to Lender of cancellation or any other change adverse to
Lender’s interests, except in the event of non-payment of premium whereby ten (10) days advance written notice will be given. Any failure of Lender to scrutinize such insurance certificates for
compliance is not a waiver of any of Lender’s rights, all of which are reserved. 
 6.3 Indemnity. Borrower agrees to indemnify and
hold Lender and its officers, directors, employees, agents, in-house attorneys, representatives and shareholders harmless from and against any and all claims, costs; expenses, damages and liabilities
(including such claims, costs, expenses, damages and liabilities based on liability in tort, including strict liability in tort), including reasonable attorneys’ fees and disbursements and other costs of investigation or defense (including
those incurred upon any appeal), that may be instituted or asserted against or incurred by Lender or any such Person as the result of credit having been extended, suspended or terminated under this Agreement and the other Loan Documents or the
administration of such credit, or in connection with or arising out of the transactions contemplated hereunder and thereunder, or any actions or failures to act in connection therewith, or arising out of the disposition or utilization of the
Collateral, excluding in all cases claims resulting solely from Lender’s gross negligence or willful misconduct. Borrower agrees to pay, and to save Lender harmless from, any and all liabilities with respect to, or, resulting from any delay in
paying, any and all excise, sales or other similar taxes (excluding taxes imposed on or measured by the net income of Lender) that may be payable or determined to be payable with respect to any of the Collateral or this Agreement. 

  
 15 

	SECTION 7.	COVENANTS OF BORROWER 

 Borrower agrees as follows: 

7.1 Financial Reports. Borrower shall furnish to Lender the following (the “Financial Statements”): 

(a) within 30 days after the end of each month, unaudited interim and
year-to-date financial statements as of the end of such month (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related
statements of income and cash flows accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that would reasonably be expected to have a
Material Adverse Effect, all certified by Borrower’s Chief Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are
subject to normal year end adjustments, and (iii) they do not contain certain non-cash items that are customarily included in quarterly and annual financial statements; 

(b) within 30 days after the end of each calendar quarter, unaudited interim and year-to-date financial statements as of the end of such calendar quarter (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash
flows accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that would reasonably be expected to have a Material Adverse Effect, certified
by Borrower’s Chief Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, and (ii) that they are subject to normal year end
adjustments; as well as the most recent capitalization table for Borrower, including the weighted average exercise price of employee stock options; 

(c) within 30 days after the end of each month, a Compliance Certificate in the form of Exhibit F; 

(d) within one hundred eighty (180) days after the end of each fiscal year, (i) unqualified audited financial statements as of the
end of such year (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal
year, certified by a firm of independent certified public accountants selected by Borrower and reasonably acceptable to Lender (Lender acknowledges that Deloitte is acceptable), accompanied by any management report from such accountants; 

(e) promptly after the sending thereof, copies of proxy statements or other reports or information that Borrower has provided generally to the
holders of its Preferred Stock, and promptly after the filing thereof, copies of any regular, periodic and special reports or registration statements that Borrower files with the Securities and Exchange Commission or any governmental authority that
may be substituted therefor, or any national securities exchange, provided that all information provided under this Section 7.1(e) shall be subject to the provisions of Section 11.12; 

  
 16 

 (f) at the same time and in the same manner as it gives to its directors, copies of all notices,
minutes, consents and other materials that Borrower provides to its directors in connection with meetings of the Board of Directors, and within 30 days after each such meeting, minutes of such meeting, provided that all information provided under
this Section 7.1(e) shall be subject to the provisions of Section 11.12; and 
 (g) financial and business projections promptly
following their approval by Borrower’s Board of Directors, as well as budgets, operating plans and other information relating to Borrower’s business reasonably requested by Lender. 

The executed Compliance Certificate and all Financial Statements required to be delivered pursuant to clauses (a), (b) and
(c) shall be sent via e-mail to financialstatements@herculestech.com with a copy to pshah@herculestech.com and bjadot@hereulestech.com provided, that if
e-mail is not available or sending such Financial Statements via e-mail is not possible, they shall be sent via facsimile to Lender at:
(650) 473-9194, attention Chief Credit Officer. 
 7.2 Management Rights. Borrower shall permit
any representative that Lender authorizes, including its attorneys and accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of Borrower at reasonable times and upon reasonable notice
during normal business hours. In addition, any such representative shall have the right to meet with management and officers of Borrower to discuss such books of account and records. In addition, Lender shall be entitled at reasonable times and
intervals to consult with and advise the management and officers of Borrower concerning significant business issues affecting Borrower. Such consultations shall not unreasonably interfere with Borrower’s business operations. The parties intend
that the rights granted Lender shall constitute “management rights” within the meaning of 29 C.F.R Section 2510.3-101(d)(3)(ii), but that any advice, recommendations or participation by Lender
with respect to any business issues shall not be deemed to give Lender, nor be deemed an exercise by Lender of, control over Borrower’s management or policies. 

7.3 Further Assurances. Borrower shall from time to time execute, deliver and file, alone or with Lender, any financing statements, security
agreements, collateral assignments, notices, control agreements, or other documents to perfect or give the priority to Lender’s Lien on the Collateral contemplated by this Agreement. Borrower shall from time to time procure any instruments or
documents as may be requested by Lender, and take all further action that may be necessary or desirable, or that Lender may reasonably request, to perfect and protect the Liens granted hereby and thereby. In addition, and for such purposes only,
Borrower hereby authorizes Lender to execute and deliver on behalf of Borrower and to file such financing statements, collateral assignments, notices, control agreements, security agreements and other documents without the signature of Borrower
either in Lender’s name or in the name of Lender as agent and attorney-in-fact for Borrower. Borrower shall protect and defend Borrower’s title to the
Collateral and Lender’s Lien thereon against all Persons claiming any interest adverse to Borrower or Lender other than Permitted Liens. 

7.4 Indebtedness. Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, or permit any
Subsidiary so to do, other than Permitted 

  
 17 

 
Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness, except for the conversion of Indebtedness into equity securities
and the payment of cash in lieu of fractional shares in connection with such conversion. 
 7.5 Collateral. Borrower shall at all times keep
the Collateral, the Intellectual Property and all other property and assets used in Borrower’s business or in which Borrower now or hereafter holds any interest free and clear from any legal process or Liens whatsoever (except for Permitted
Liens), and shall give Lender prompt written notice of any material legal proceedings affecting the Collateral, the Intellectual Property, such other property and assets, or any Liens thereon. Borrower shall cause its Subsidiaries to protect and
defend such Subsidiary’s title to its assets from and against all Persons claiming any interest adverse to such Subsidiary, and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary’s property and assets free and clear
from any legal process or Liens whatsoever (except for Permitted Liens), and shall give Lender prompt written notice of any legal process affecting such Subsidiary’s assets. Borrower shall not agree with any Person other than Lender not to
encumber its property. 
 7.6 Investments. Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any
Person, or permit any of its Subsidiaries so to do, other than Permitted Investments. 
 7.7 Distributions. Borrower shall not, and shall
not allow any Subsidiary to, (a) repurchase or redeem any class of stock or other equity interest other than pursuant to employee, director or consultant repurchase plans or other similar agreements, provided, however, in each case the
repurchase or redemption price does not exceed the original consideration paid for such stock or equity interest, or (b) declare or pay any cash dividend or make a cash distribution on any class of stock or other equity interest, except that a
Subsidiary may pay dividends or make distributions to Borrower, or (c) lend money to any employees, officers or directors or guarantee the payment of any such loans granted by a third party in excess of $100,000 in the aggregate or
(d) waive, release or forgive any indebtedness owed by any employees, officers or directors in excess of $100,000 in the aggregate. 

7.8 Transfers. Except for Permitted Transfers, Borrower shall not voluntarily or involuntarily transfer, sell, lease, license, lend or in any
other manner convey any equitable, beneficial or legal interest in any material portion of their assets. 
 7.9 Mergers or Acquisitions.
Borrower shall not merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into any other business organization (other than mergers or consolidations of a Subsidiary into another Subsidiary or into Borrower), or
acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person. 
 7.10
Taxes. Borrower and its Subsidiaries shall pay when due all taxes, fees or other charges of any nature whatsoever (together with any related interest or penalties) now or hereafter imposed or assessed against Borrower, Lender or the Collateral or
upon Borrower’s ownership, possession, use, operation or disposition thereof or upon Borrower’s rents, receipts or earnings arising therefrom. Borrower shall file on or before the due date therefor all personal

  
 18 

 
property tax returns in respect of the Collateral. Notwithstanding the foregoing, Borrower may contest, in good faith and by appropriate proceedings, taxes for which Borrower maintains adequate
reserves therefor in accordance with GAAP. 
 7.11 Corporate Changes. Neither Borrower nor any Subsidiary shall change its corporate name,
legal form or jurisdiction of formation without ten (10) days’ prior written notice to Lender. Neither Borrower nor any Subsidiary shall suffer a Change in Control. Neither Borrower nor any Subsidiary shall relocate its chief executive
office or its principal place of business unless: (i) it has provided prior written notice to Lender; and (ii) such relocation shall be within the continental United States. Neither Borrower nor any Subsidiary shall relocate any item of
tangible Collateral (other than (x) sales of Inventory in the ordinary course of business, (y) relocations of Equipment having an aggregate value of up to $150,000 in any fiscal year, and relocations of Collateral from a location described
on Exhibit C to another location described on Exhibit C) unless (i) it has provided prompt written notice to Lender, (ii) such relocation is within the continental United States and, (iii) if such relocation is to a third party
bailee, it has delivered a bailee agreement in form and substance reasonably acceptable to Lender. 
 7.12 Deposit Accounts. Neither
Borrower nor any Subsidiary shall maintain any Deposit Accounts, or accounts holding Investment Property, except with respect to which Lender has an Account Control Agreement. 

7.13 Borrower shall notify Lender of each material Subsidiary formed subsequent to the Closing Date and, within 15 days of formation, shall
cause any such Subsidiary organized under the laws of any State within the United States to execute and deliver to Lender a Joinder Agreement. 

7.14 Lender has received a license from the U.S. Small Business Administration (“SBA”) to extend loans as a small business
investment company (“SBIC”) pursuant to the Small Business Investment Act of 1958, as amended, and the associated regulations (collectively, the “SBIC Act”). Portions of the loan to Borrower will be made under the SBA
license and the SBIC Act. Addendum 1 to this Agreement outlines various responsibilities of Lender and Borrower associated with an SBA loan, and such Addendum 1 is hereby incorporated in this Agreement. 

 

	SECTION 8.	RIGHT TO INVEST OR CONVERT 

 8.1 Lender or its assignee or nominee may, in its
discretion, participate in the Subsequent Financing in an amount of up to $500,000 upon the occurrence of the Subsequent Financing on the same terms, conditions and pricing afforded to others participating in the Subsequent Financing. Lender or its
assignee or nominee may also, in its discretion and subject to Borrower’s consent, convert up to $1,000,000 of the outstanding principal balance hereunder on the same terms, conditions and pricing afforded to others participating in the
Subsequent Financing. 

  
 19 

	SECTION 9.	EVENTS OF DEFAULT 

 The occurrence of any one or more of the following events
shall be an Event of Default: 
 9.1 Payments. Borrower fails to pay any amount due under this Agreement, the Notes or any of the other Loan
Documents on the due date; or 
 9.2 Covenants. Borrower breaches or defaults in the performance of any covenant or Secured Obligation under
this Agreement, the Notes, or any of the other Loan Documents, and (a) with respect to a default under any covenant under this Agreement (other than under Sections 6, 7.5, 7.6, 7.7, 7.8, 7.9 or 7.14) such default continues for more than
ten (10) days after the earlier of the date on which (i) Lender has given notice of such default to Borrower and (ii) Borrower has actual knowledge of such default or (b) with respect to a default under any of Sections 6,
7.5, 7.6, 7.7, 7.8, 7.9 or 7.14, the occurrence of such default; or 
 9.3 Material Adverse Effect. A circumstance has occurred that would
reasonably be expected to have a Material Adverse Effect; or 
 9.4 Other Loan Documents. The occurrence of any default under any Loan
Document or any other agreement between Borrower and Lender and such default continues for more than ten (10) days after the earlier of (a) Lender has given written notice of such default to Borrower, or (b) Borrower has actual
knowledge of such default; or 
 9.5 Representations. Any representation or warranty made by Borrower in any Loan Document or in the Warrant
shall have been false or misleading in any material respect; or 
 9.6 Insolvency. Borrower (A) (i) shall make an assignment for
the benefit of creditors; or (ii) shall be unable to pay its debts as they become due or be unable to pay or perform under the Loan Documents, or shall become insolvent; or (iii) shall file a voluntary petition in bankruptcy; or
(iv) shall file any petition, answer, or document seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation pertinent to such
circumstances; or (v) shall seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of Borrower or of all or any substantial part (i.e., 33-1/3% or more) of the
assets or property of Borrower; or (vi) shall cease operations of its business as its business has nominally been conducted, or terminate substantially all of its employees; or (vii) Borrower or its directors or majority shareholders shall
take any action initiating any of the foregoing actions described in clauses (i) through (vi); or (B) either (i) forty five (45) days shall have expired after the commencement of an involuntary action against Borrower
seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, without such action being dismissed or all orders or proceedings thereunder affecting
the operations or the business of Borrower being stayed; or (ii) a stay of any such order or proceedings shall thereafter be set aside and the action setting it aside shall not be timely appealed; or (iii) Borrower shall file any answer
admitting or not contesting the material allegations of a petition filed against Borrower in any such proceedings; or (iv) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such
proceedings; or (v) forty five (45) days shall have expired after the appointment, without the consent or acquiescence of Borrower, of any trustee, receiver or liquidator of Borrower or of all or any substantial part of the properties of
Borrower without such appointment being vacated; or 

  
 20 

 9.7 Attachments; Judgments. Any portion of Borrower’s assets is attached or seized, or a
levy is filed against any such assets, or a judgment or judgments is/are entered for the payment of money, individually or in the aggregate, of at least $100,000, or Borrower is enjoined or in any way prevented by court order from conducting any
part of its business; or 
 9.8 Other Obligations. The occurrence of any default under any agreement or obligation of Borrower involving any
Indebtedness in excess of $100,000, or the occurrence of any default under any agreement or obligation of Borrower that could reasonably be expected to have a Material Adverse Effect. 

 

	SECTION 10.	REMEDIES 

 10.1 General. Upon and during the continuance of any one or more Events
of Default, (i) Lender may, at its option, accelerate and demand payment of all or any part of the Secured Obligations together with the Prepayment Charge and declare them to be immediately due and payable (provided, that upon the occurrence of
an Event of Default of the type described in Section 9.6, the Notes and all of the Secured Obligations shall automatically be accelerated and made due and payable, in each case without any further notice or act), and (ii) Lender may notify
any of Borrower’s account debtors to make payment directly to Lender, compromise the amount of any such account on Borrower’s behalf and endorse Lender’s name without recourse on any such payment for deposit directly to Lender’s
account. Lender may exercise all rights and remedies with respect to the Collateral under the Loan Documents or otherwise available to it under the UCC and other applicable law, including the right to release, hold, sell, lease, liquidate, collect,
realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy, utilize, process and commingle the Collateral. All Lender’s rights and remedies shall be cumulative and not exclusive. 

10.2 Collection; Foreclosure. Upon the occurrence and during the continuance of any Event of Default, Lender may, at any time or from time to
time, apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable preparation or processing, in such order as Lender may elect. Any
such sale may be made either at public or private sale at its place of business or elsewhere. Borrower agrees that any such public or private sale may occur upon ten (10) calendar days’ prior written notice to Borrower. Lender may require
Borrower to assemble the Collateral and make it available to Lender at a place designated by Lender that is reasonably convenient to Lender and Borrower. The proceeds of any sale, disposition or other realization upon all or any part of the
Collateral shall be applied by Lender in the following order of priorities: 
 First, to Lender in an amount sufficient to pay in full
Lender’s costs and professionals’ and advisors’ fees and expenses as described in Section 11.11; 
 Second, to Lender in
an amount equal to the then unpaid amount of the Secured Obligations (including principal, interest, and the Default Rate interest), in such order and priority as Lender may choose in its sole discretion; and 

  
 21 

 Finally, after the full, final, and indefeasible payment in Cash of all of the Secured
Obligations, to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives or as a court of competent jurisdiction may direct. 

Lender shall be deemed to have acted reasonably in the custody, preservation and disposition of any of the Collateral if it complies with the obligations of a
secured party under the UCC. 
 10.3 No Waiver. Lender shall be under no obligation to marshal any of the Collateral for the benefit of
Borrower or any other Person, and Borrower expressly waives all rights, if any, to require Lender to marshal any Collateral. 
 10.4
Cumulative Remedies. The rights, powers and remedies of Lender hereunder shall be in addition to all rights, powers and remedies given by statute or rule of law and are cumulative. The exercise of any one or more of the rights, powers and remedies
provided herein shall not be construed as a waiver of or election of remedies with respect to any other rights, powers and remedies of Lender. 
  

	SECTION 11.	MISCELLANEOUS 

 11.1 Severability. Whenever possible, each provision of this
Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and
duration of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. 

11.2 Notice. Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other
communication (including the delivery of Financial Statements) that is required, contemplated, or permitted under the Loan Documents or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served,
given, delivered, and received upon the earlier of: (i) the day of transmission by facsimile or hand delivery or delivery by an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in
the United States mails, with proper first class postage prepaid, in each case addressed to the party to be notified as follows: 
 (a) If
to Lender: 
 HERCULES TECHNOLOGY II, L.P. 

Legal Department 
 Attention:
Chief Legal Officer and Parag Shah 
 400 Hamilton Avenue, Suite 310 

Palo Alto, CA 94301 
 Facsimile: 650-473-9194 
 Telephone: 650-289-3068 

  
 22 

 (b) If to Borrower: 

DICERNA PHARMACEUTICALS, INC. 

480 Arsenal Street, Building 1 

Suite 120 
 Watertown, MA 02472

 Attention: James Jenson, Chief Executive Officer 

Facsimile: 
 Telephone: 

With a copy to: 
 MINTZ LEVIN
COHN FERRIS GLOVSKY AND POPEO, P.C. 
 One Financial Center 

Boston, MA 02111 
 Attention: John
Cheney, Esquire 
 Facsimile: 617-542-2241 

Telephone: 617-542-6000 

or to such other address as each party may designate for itself by like notice. Any notice delivered to a party in accordance with this
Section will be effective despite the failure to provide a copy of that notice to any person not party to this Agreement. 
 11.3 Entire
Agreement; Amendments. This Agreement, the Notes, and the other Loan Documents constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and thereof, and supersede and replace in their entirety
any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof or thereof (including Lender’s revised proposal letter dated January 21, 2009).
None of the terms of this Agreement, the Notes or any of the other. Loan Documents may be amended except by an instrument executed by each of the parties hereto. 

11.4 No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an
ambiguity or question of intent or interpretation arises; this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement. 
 11.5 No Waiver. The powers conferred upon Lender by this Agreement are solely to protect its rights
hereunder and under the other Loan Documents and its interest in the Collateral and shall not impose any duty upon Lender to exercise any such powers. No omission or delay by Lender at any time to enforce any right or remedy reserved to it, or to
require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver of any such right or remedy to which Lender is entitled, nor shall it in any way affect the right of Lender to enforce such
provisions thereafter. 
 11.6 Survival. All agreements, representations and warranties contained in this Agreement, the Notes and the other
Loan Documents or in any document delivered pursuant hereto or thereto shall be for the benefit of Lender and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement. 

  
 23 

 11.7 Successors and Assigns. The provisions of this Agreement and the other Loan Documents shall
inure to the benefit of and be binding on Borrower and its permitted assigns (if any). Borrower shall not assign its obligations under this Agreement, the Notes or any of the other Loan Documents without Lender’s express prior written
consent, and any such attempted assignment shall be void and of no effect. Lender may assign, transfer, or endorse its rights hereunder and under the other Loan Documents without prior notice to Borrower, and all of such rights shall inure to the
benefit of Lender’s successors and assigns. 
 11.8 Governing Law. This Agreement, the Notes and the other Loan Documents have been
negotiated and delivered to Lender in the State of California, and shall have been accepted by Lender in the State of California. Payment to Lender by Borrower of the Secured Obligations is due in the State of California. This Agreement, the Notes
and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 

11.9 Consent to Jurisdiction and Venue. All judicial proceedings (to the extent that the reference requirement of Section 11.10 is not
applicable) arising in or under or related to this Agreement, the Notes or any of the other Loan Documents may be brought in any state or federal court located in the State of California. By execution and delivery of this Agreement, each party
hereto generally and unconditionally: (a) consents to nonexclusive personal jurisdiction in Santa Clara County, State of California; (b) waives any objection as to jurisdiction or venue in Santa Clara County, State of California;
(c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement, the Notes or the other Loan
Documents. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 11.2, and shall be deemed effective and
received as set forth in Section 11.2. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. 

11.10 Mutual Waiver of Jury Trial / Judicial Reference. 

(a) Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced
and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF BORROWER AND LENDER SPECIFICALLY
WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY BORROWER AGAINST
LENDER OR ITS ASSIGNEE OR BY LENDER OR ITS ASSIGNEE AGAINST BORROWER. This waiver extends to all such Claims, including Claims that involve Persons other than Borrower and Lender; Claims that arise out of or are in any way connected to the
relationship between Borrower and Lender; and any Claims for damages, breach of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other Loan Document. 

  
 24 

 (b) If the waiver of jury trial set forth in Section 11.10(a) is ineffective or
unenforceable, the parties agree that all Claims shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a mutually acceptable referee or, if the parties cannot agree, a
referee selected by the Presiding Judge of the Santa Clara County, California. Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable to such proceeding. 

(c) In the event Claims are to be resolved by judicial reference, either party may seek from a court identified in Section 11.9, any
prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial reference. 

11.11 Professional Fees. Borrower promises to pay Lender’s fees and expenses necessary to finalize the loan documentation, including but
not limited to reasonable attorneys fees, UCC searches, filing costs, and other miscellaneous expenses. In addition, Borrower promises to pay any and all reasonable attorneys’ and other professionals’ fees and expenses (including fees and
expenses of in-house counsel) incurred by Lender after the Closing Date in connection with or related to: (a) the Loan; (b) the administration, collection, or enforcement of the Loan; (c) the
amendment or modification of the Loan Documents; (d) any waiver, consent, release, or termination under the Loan Documents; (e) the protection, preservation, sale, lease, liquidation, or disposition of Collateral or the exercise of
remedies with respect to the Collateral; (f) any legal, litigation, administrative, arbitration, or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review thereof; and (g) any
bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to Borrower, the Collateral, the Loan Documents, including representing Lender in any adversary proceeding or contested
matter commenced or continued by or on behalf of Borrower’s estate, and any appeal or review thereof. 
 11.12 Confidentiality. Lender
acknowledges that certain items of Collateral and information provided to Lender by Borrower are confidential and proprietary information of Borrower, whether or not marked as confidential by Borrower at the time of disclosure (the
“Confidential Information”). Accordingly, Lender agrees that any Confidential Information it may obtain in the course of acquiring, administering, or perfecting Lender’s security interest in the Collateral shall not be disclosed to
any other person or entity in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except that Lender may disclose any such information: (a) to its own directors, officers, employees, accountants, counsel
and other professional advisors and to its affiliates if Lender in its sole discretion determines that any such party should have access to such information in connection with such party’s responsibilities in connection with the Loan or this
Agreement and, provided that such recipient of such Confidential Information either (i) agrees to be bound by the confidentiality provisions of this paragraph or (ii) is otherwise subject to confidentiality restrictions that reasonably
protect against the disclosure of Confidential Information; (b) if such information is generally available to the public; (c) if required or appropriate in any report, statement or testimony submitted to any governmental authority having
or claiming to have jurisdiction over Lender; (d) if required or appropriate in response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable by Lender’s counsel; (e) to comply
with any legal requirement or law applicable to Lender; (f) to the extent reasonably necessary in connection 

  
 25 

 
with the exercise of any right or remedy under any Loan Document, including Lender’s sale, lease, or other disposition of Collateral after default; (g) to any participant or assignee of
Lender or any prospective participant or assignee; provided, that such participant or assignee or prospective participant or assignee agrees in writing to be bound by this Section prior to disclosure; or (h) otherwise with the prior consent of
Borrower; provided, that any disclosure made in violation of this Agreement shall not affect the obligations of Borrower or any of its affiliates or any guarantor under this Agreement or the other Loan Documents. 

11.13 Assignment of Rights. Borrower acknowledges and understands that Lender may sell and assign all or part of its interest hereunder and
under the Note(s) and Loan Documents to any person or entity (an “Assignee”). After such assignment the term “Lender” as used in the Loan Documents shall mean and include such Assignee, and such Assignee shall be vested with all
rights, powers and remedies of Lender hereunder with respect to the interest so assigned; but with respect to any such interest not so transferred, Lender shall retain all rights, powers and remedies hereby given. No such assignment by Lender shall
relieve Borrower of any of its obligations hereunder. Lender agrees that in the event of any transfer by it of the Note(s), it will endorse thereon a notation as to the portion of the principal of the Note(s), which shall have been paid at the time
of such transfer and as to the date to which interest shall have been last paid thereon. 
 11.14 Revival of Secured Obligations. This
Agreement and the Loan Documents shall remain in full force and effect and continue to be effective if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment for the
benefit of creditors, if a receiver or trustee is appointed for all or any significant part of Borrower’s assets, or if any payment or transfer of Collateral is recovered from Lender. The Loan Documents and the Secured Obligations and
Collateral security shall continue to be effective or shall be revived or reinstated, as the case may be, if at any time payment and performance of the Secured Obligations or any transfer of Collateral to Lender, or any part thereof is rescinded,
avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is recovered from, Lender or by any obligee of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or
otherwise, all as though such payment, performance, or transfer of Collateral had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and
the Secured Obligations shall be deemed, without any further action or documentation, to have been revived and reinstated except to the extent of the full, final, and indefeasible payment to Lender in Cash. 

11.15 Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts,
and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. 

11.16 No Third Party Beneficiaries. No provisions of the Loan Documents are intended, nor will be interpreted, to provide or create any third-party beneficiary rights or any other rights of any kind in any person other than Lender and Borrower unless specifically provided otherwise herein, and, except as otherwise so provided, all provisions of the
Loan Documents will be personal and solely between the Lender and the Borrower. 

  
 26 

 11.17 Publicity. With Borrower’s prior written consent, which shall not be unreasonably
withheld, Lender may use Borrower’s name and logo, and include a brief description of the relationship between Borrower and Lender, in Lender’s marketing materials. 

(SIGNATURES TO FOLLOW) 

  
 27 

 IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Loan and Security
Agreement as of the day and year first above written. 
  

			
	BORROWER:
	
	DICERNA PHARMACEUTICALS, INC.
		
	Signature:	 	 /s/ James C. Jenson, Ph.D.

		
	Print Name:	 	 James C. Jenson, Ph.D.

		
	Title:	 	 President and Chief Executive Officer

 Accepted in Palo Alto, California: 

 

			
	LENDER:
	
	HERCULES TECHNOLOGY II, L. P., a Delaware limited partnership
	
	By: Hercules Technology SBIC Management, LLC, its general partner
	
	By: Hercules Technology Growth Capital, Inc., its Manager
		
	Signature:	 	  

		
	Print Name:	 	  

		
	Title:	 	  

  
 28 

 IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Loan and Security
Agreement as of the day and year first above written. 
  

			
	BORROWER:
	
	DICERNA PHARMACEUTICALS, INC.
		
	Signature:	 	  

		
	Print Name:	 	  

		
	Title:	 	  

 Accepted in Palo Alto, California: 

 

			
	LENDER:
	
	HERCULES TECHNOLOGY II, L. P., a Delaware limited partnership
	
	By: Hercules Technology SBIC Management, LLC, its general partner
	
	By: Hercules Technology Growth Capital, Inc., its Manager
		
	Signature:	 	 /s/ K. Nicholas Martitsch

		
	Print Name:	 	 K. Nicholas Martitsch

		
	Title:	 	 Associate General Counsel

  
 29 

 AMENDMENT NO. 1 

TO 
 LOAN AND SECURITY
AGREEMENT 
 THIS AMENDMENT NO. 1 TO LOAN
AND SECURITY AGREEMENT (this “Amendment”) is entered into this 28th day of May, 2010, by and between DICERNA
PHARMACEUTICALS, INC., a Delaware corporation, and each of its subsidiaries (hereinafter collectively referred to as “Borrower”), and HERCULES
TECHNOLOGY II, L.P., a Delaware limited partnership (“Lender”). Capitalized terms used herein without definition shall have the same meanings given them in the Loan Agreement (as defined
below). 
 RECITALS 

A. Borrower and Lender have entered into that certain Loan and Security Agreement dated as of March 25, 2009, (as may be amended,
restated, or otherwise modified, the “Loan Agreement,” pursuant to which Lender has agreed to extend and make available to Borrower certain advances of money. 

B. Borrower and Lender have agreed to amend the Loan Agreement upon the terms and conditions more fully set forth herein. 

AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing Recitals and intending to be legally bound, the parties hereto agree as follows: 

1. AMENDMENTS. 

1.1 SECTION 1 The definition of Term Loan Maturity Date is deleted in its entirety and replaced with the following:

 “Term Loan Maturity Date” means July 1, 2012. 

1.2 SECTION 2.1 Section 2.1(d) of the Loan Agreement is amended by adding the following proviso to the end of
the section: 
 “Notwithstanding anything to the contrary in the Loan Agreement, the June 2010, July 2010, and August 2010
principal payments due under the Loan Agreement (the “Deferred Principal Payments”) shall not become due and payable as set forth therein, but instead shall be deferred. The Deferred Principal Payments shall be added to the
remaining principal amount outstanding under the Loan and re-amortized in equal monthly payments of principal and interest over the remaining life of the loan as set forth in the Loan Agreement.” 

  
 1 

 2. BORROWER’S REPRESENTATIONS
AND WARRANTIES. Borrower represents and warrants that: 
 (a) immediately upon
giving effect to this Amendment (i) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties
relate to an earlier date, in which case they are true and correct as of such date), and (ii) no Event of Default has occurred and is continuing with respect to which Borrower has not been notified in writing by Lender; 

(b) Borrower has the corporate power and authority to execute and deliver this Amendment and to perform its obligations under the Loan
Agreement, as amended by this Amendment; 
 (c) the certificate of incorporation, bylaws and other organizational documents of
Borrower delivered to Lender on the Closing Date remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect; 

(d) the execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, have been duly authorized by all necessary corporate action on the part of Borrower; 
 (e)
this Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against it in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization,
liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights; and 

(f) as of the date hereof, it has no defenses against the obligations to pay any amounts under the Obligations. Borrower acknowledges
that Lender has acted in good faith and has conducted in a commercially reasonable manner its relationships with Borrower in connection with this Amendment and in connection with the Loan Documents. 

(g) Borrower understands and acknowledges that Lender is entering into this Amendment in reliance upon, and in partial consideration
for, the above representations and warranties, and agrees that such reliance is reasonable and appropriate. 
 3.
LIMITATION. The amendments set forth in this Amendment shall be limited precisely as written and shall not be deemed (a) to be a waiver or modification of any other term or condition of the Loan Agreement or of
any other instrument or agreement referred to therein or to prejudice any right or remedy which Lender may now have or may have in the future under or in connection with the Loan Agreement or any instrument or agreement referred to therein; or
(b) to be a consent to any future amendment or modification or waiver to any instrument or agreement the execution and delivery of which is consented to hereby, or to any waiver of any of the provisions thereof. Except as expressly amended
hereby, the Loan Agreement shall continue in full force and effect. 

  
 2 

 4. EFFECTIVENESS. This Amendment shall become effective upon
the satisfaction of all the following conditions precedent: 
 4.1 Amendment. Borrower and Lender shall have duly executed and
delivered this Amendment to Lender. 
 4.2 Amendment Fee. Borrower shall pay to Lender with respect to this Amendment, a fully earned,
non-refundable loan amendment fee in an amount of $35,000. 
 5. COUNTERPARTS. This Amendment may be
signed in any number of counterparts, and by different parties hereto in separate counterparts, with the same effect as if the signatures to each such counterpart were upon a single instrument. All counterparts shall be deemed an original of this
Amendment. 
 6. INTEGRATION. This Amendment and any documents executed in connection herewith or
pursuant hereto contain the entire agreement between the parties with respect to the subject matter hereof and supersede all prior agreements, understandings, offers and negotiations, oral or written, with respect thereto and no extrinsic evidence
whatsoever may be introduced in any judicial or arbitration proceeding, if any, involving this Amendment; except that any financing statements or other agreements or instruments filed by Lender with respect to Borrower shall remain in full force and
effect. 
 7. GOVERNING LAW; VENUE. THIS AMENDMENT SHALL BE GOVERNED BY
AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA. Borrower and Lender each submit to the exclusive jurisdiction of the State and Federal courts in Santa Clara County, California. 

[signature page follows] 

  
 3 

 IN WITNESS WHEREOF, the parties have duly
authorized and caused this Amendment to be executed as of the date first written above. 
 BORROWER: 

DICERNA PHARMACEUTICALS, INC. 
  

			
	By:	 	 /s/ Douglas Fambrough

		
	Name:	 	 Douglas Fambrough

		
	Title:	 	 CEO

 LENDER: 

HERCULES TECHNOLOGY II, L.P. 

a Delaware limited partnership 
 By: Hercules Technology SBIC

 Management, LLC, its General Partner 
 By: Hercules
Technology Growth Capital Inc., 
 its Manager 
  

			
	By:	 	 /s/ K. Nicholas Martitsch

		
	Name:	 	K. Nicholas Martitsch
		
	Title:	 	Associate General Counsel

  
 4 

 SECOND AMENDMENT 

TO 
 LOAN AND SECURITY
AGREEMENT 
 THIS SECOND AMENDMENT TO LOAN AND
SECURITY AGREEMENT (this “Amendment”) is entered into as of June 28, 2011, by and between HERCULES TECHNOLOGY II, L.P. (“Lender”) and DICERNA
PHARMACEUTICALS, INC., a Delaware corporation, and each of its subsidiaries, (hereinafter collectively referred to as the “Borrower”). 

RECITALS 

Borrower and Lender are parties to that certain Loan and Security Agreement dated as of March 25, 2009, as amended from time to time,
including a First Amendment to Loan and Security Agreement dated as of May 28, 2010 (the “Agreement”). The parties desire to amend the Agreement in accordance with the terms of this Amendment. Unless otherwise defined herein,
capitalized terms in this Amendment shall have the meanings assigned in the Agreement. 
 NOW,
THEREFORE, the parties agree as follows: 
 1. The following definitions in Section 1.1 of the
Agreement are hereby added or amended to read as follows: 
 “Advance” means a Term Loan Advance or a Second Term Loan Advance.

 “Amendment Date” means June 28, 2011. 

“Maximum Term Loan Amount” means Twelve Million Dollars ($12,000,000). 

“Next Round” means the first sale in a venture capital financing by Borrower of its equity or convertible debt securities (post
Series B) that closes after the Amendment Date in which Borrower receives gross proceeds of at least $5,000,000. 
 “Second Term Loan
Advance” means an Advance made under Section 2.1.1. 
 “Term Loan Maturity Date” means January 2, 2015. 

2. Section 2.1.1 is added to the Agreement, as follows: 

2.1.1 Term Loan. 
 (a)
Advances. Subject to the terms and conditions of this Agreement, Lender will make, and Borrower agrees to draw, a Second Term Loan Advance of $7,000,000 on the Closing Date. Borrower shall use the first proceeds of the Second Term Loan Advance to
repay the entire principal balance of the outstanding Term Loan Advance and all accrued but unpaid interest (provided the End of Term Charge shall not be paid out of such proceeds, and shall 

  
 1 

 
remain due on July 1, 2012). Borrower may request additional Second Term Loan Advances in an aggregate amount of up to the Maximum Term Loan Amount minus the outstanding principal balance of
the Second Term Loan Advances, from the Amendment Date through December 15, 2011. 
 (b) Advance Request. To obtain a Second
Term Loan Advance, Borrower shall complete, sign and deliver an Advance Request and Term Note to Lender. Lender shall fund the Second Term Loan Advance in the manner requested by the Advance Request provided that each of the conditions precedent to
such Second Term Loan Advance is satisfied as of the requested Advance Date. 
 (c) Interest. The principal balance of each Second
Term Loan Advance shall bear interest thereon from such Advance Date at a floating rate equal to the greater of (i) 10.15% or (ii) the sum of 10.15% plus the Prime Rate minus 5.75%, not in any case to exceed 12.75% per annum, in all
cases based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed Such rate will float and change on the day the Prime Rate changes from time to time. 

(d) Payment. Borrower will pay interest on each Second Term Loan Advance on the first day of each month, beginning the month after the
Advance Date. Borrower shall repay the aggregate principal balance of Second Term Loan Advances that is outstanding on March 31, 2012 in equal monthly installments of principal and interest beginning April 1, 2012 and continuing
on the first business day of each month thereafter through the Term Loan Maturity Date (for clarity, the principal and interest components of equal installments may vary if the interest rate changes). The entire Term Loan principal balance and all
accrued but unpaid interest hereunder, shall be due and payable on the Term Loan Maturity Date. Borrower shall make all, payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense. Lender will
initiate debit entries to the Borrower’s account as authorized on the ACH Authorization on each payment date of all periodic obligations payable to Lender. On or about the Amendment Date, Lender will provide an amortization schedule to Borrower
showing the payments and respective due dates. Lender will provide a revised schedule after any changes to the applicable interest rate. 

(e) Prepayment. At its option upon at least 7 business days prior notice to Lender, Borrower may prepay all or any portion (provided
that any prepayments made on less than the entire principal balance will be made in an amount no less than $500,000) of the outstanding Second Term Loan Advance by paying the principal amount being prepaid, all accrued and unpaid interest, together
with a prepayment fee equal to the following percentage of the Advance amount being prepaid: if such Second Term Loan Advance amounts are prepaid in any of the first twelve (12) months following the Amendment Date, 3.0%; after twelve
(12) months but prior to twenty four (24) months, 2.0%; and thereafter, 1.0%. Borrower agrees that the prepayment fee is a reasonable calculation of Lender’s lost profits in view of the difficulties and impracticality of determining
actual damages resulting from an early repayment of the Second Term Loan Advance. Borrower shall prepay the outstanding amount of all principal and accrued and unpaid interest upon a Change in Control; provided, however, that for purposes of the
foregoing, a “Change in Control” shall not include any bona fide equity financing transaction the primary purpose of which is to raise capital for the Borrower; provided, that the investors participating in any such transaction shall be
acceptable to the Lender in its reasonable judgment. 

  
 2 

 3. Lender or its assignee or nominee may, in its discretion, participate in the Next Round
in an amount of up to $1,000,000 upon the occurrence of the Next Round on the same terms, conditions and pricing afforded to others participating in the Next Round. Lender or its assignee or nominee may also, in its discretion and subject to
Borrower’s consent, convert up to $1,000,000 of the outstanding principal balance of the Second Term Loan Advances into equity securities of the Borrower on the same terms, conditions and pricing afforded to others participating in the Next
Round. 
 4. Unless otherwise defined, all initially capitalized terms in this Amendment shalt be as defined in the Agreement.
The Agreement, as amended hereby, shall remain in full force and effect in accordance with its terms. Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an
amendment of, any right, power, or remedy of Lender under the Loan Documents, as in effect prior to the date hereof. 
 5.
Borrower ratifies and reaffirms the continuing effectiveness of all agreements entered into in connection with the Agreement. Borrower confirms that the representations and warranties set forth in Section 5 of the Agreement are true and
correct in all material respects, and that an Event of Default has not occurred and is not continuing. 
 6. This Amendment
may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument. 

7. As a condition to the effectiveness of this Amendment, Lender shall have received, in form and substance satisfactory to Lender, the
following: 
 (a) this Amendment, duly executed by Borrower; 

(b) Corporate Resolutions to Borrow; 

(c) Warrant to Purchase Stock; 

(d) An insurance certificate; and 

(e) payment of an amendment fee equal to $60,000 (Lender acknowledges prior receipt of $30,000 to be applied against such fee) plus an
amount equal to the Lender Expenses incurred in connection with this Amendment. 

  
 3 

 IN WITNESS WHEREOF, the
undersigned have executed this Amendment as of the first date above written. 
  

			
	DICERNA PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Douglas Fambrough

		
	Title:	 	 CEO

	
	HERCULES TECHNOLOGY II, L.P., a Delaware limited partnership
	
	By: Hercules Technology SBIC Management, LLC, its general partner
	
	By: Hercules Technology Growth Capital, Inc., its Manager
		
	By:	 	  

		
	Title:	 	  

  
 4 

 IN WITNESS WHEREOF, the
undersigned have executed this Amendment as of the first date above written. 
  

			
	DICERNA PHARMACEUTICALS, INC.
		
	By:	 	  

		
	Title:	 	  

	
	HERCULES TECHNOLOGY II, L.P., a Delaware limited partnership
	
	By: Hercules Technology SBIC Management, LLC, its general partner
	
	By: Hercules Technology Growth Capital, Inc., its Manager
		
	By:	 	 /s/ K. Nicholas Martitsch

		
	Title:	 	 Associate General Counsel

  
 5EX-10.20

 Exhibit 10.20 

***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
 EXCLUSIVE LICENSE AGREEMENT 

THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and entered into as of the 28th day of September, 2007 (the “Effective
Date”) by and between Dicerna Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 14 Peterson Circle, Sudbury, MA 01776 (“Dicerna”) and City of Hope, a California nonprofit public benefit corporation
located at 1500 East Duarte Road, Duarte, California 91010 (“COH”). Dicerna and COH are each sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

WHEREAS: 
 A. COH operates an academic research
and medical center that encourages the use of its inventions, discoveries and intellectual property for the benefit of the public and COH owns or Controls certain Patent Rights (as defined below) useful in the Field (as defined below); 

B. Dicerna is a company to be dedicated to the commercial development, and exploitation of products that incorporate one or more of the technologies described
in the Patent Rights for the diagnosis, prevention or treatment of diseases in humans and therefore desires to obtain from COH a worldwide, exclusive license under the Patent Rights, as more particularly set forth herein; and 

C. COH is willing to grant such a license to Dicerna on the terms and subject to the conditions set forth herein. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the amount and sufficiency of
which are hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE 1: DEFINITIONS 

1.1 “Affiliate” of a Party means a Person that, directly or indirectly (through one or more intermediaries) controls, is
controlled by, or is under common control with such Party. For purposes of this Section 1.1, “control” means (i) the direct or indirect ownership of 50 percent or more of the voting stock or other voting interests or interests in
profits, or (ii) the ability to otherwise control or direct the decisions of board of directors or equivalent governing body thereof. 

1.2 “Business Day” means any day, other than a Saturday, Sunday or day on which commercial banks located in Los Angeles,
California, are authorized or required by law or regulation to close. 
 1.3 “Commercially Reasonable Efforts” means [***].
[***]. 
 1.4 “COH Confidential Information” means Confidential Information disclosed or provided by, or on behalf of, COH
to Dicerna or its designees. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 1.5
“Confidential Information” means: (i) all information and materials (of whatever kind and in whatever form or medium) disclosed by or on behalf of a Party to the other Party (or its designee) in connection with this Agreement,
whether prior to or during the term of this Agreement and whether provided orally, electronically, visually, or in writing; (ii) all copies of the information and materials described in (i) above; and (iii) the existence and each of
the terms and conditions of this Agreement. Confidential Information shall not include information and materials, to the extent a Party can demonstrate, through its contemporaneous written records, that such information and materials are or have
been: 
 (a) known to the receiving Party, or in the public domain, at the time of its receipt by a Party, or which thereafter becomes part
of the public domain other than by virtue of a breach of this Agreement or the obligations of confidentiality under this Agreement; 
 (b)
received without an obligation of confidentiality from a Third Party having the right to disclose without restrictions such information; 

(c) independently developed by the receiving Party without use of or reference to Confidential Information disclosed by the other Party; or

 (d) released from the restrictions set forth in this Agreement by the express prior written consent of the disclosing Party. 

1.6 “Control(s)” or “Controlled” means the possession by a Party, as of the Effective Date or during the
term of this Agreement, of: (i) with respect to materials, data or information, physical possession or the right to such physical possession of those items, with the right to provide them to Third Parties; and (ii) with respect to
intellectual property rights, rights sufficient to grant the applicable license or sublicense under this Agreement, without violating the terms of any agreement with any Third Party. 

1.7 “Covers” or “Covered by,” with reference to a particular Licensed Product means that the making, using,
selling, offering for sale, or importing of such Licensed Product would, but for ownership of, or a license granted under this Agreement to, the relevant Patent Right infringe a Valid Claim in the country in which the activity occurs. 

1.8 “Dicerna Confidential Information” means Confidential Information disclosed or provided by, or on behalf of, Dicerna to
COH or its designees. 
 1.9 “Dispute” means any controversy, claim or legal proceeding arising out of or relating to this
Agreement, or the interpretation, breach, termination, or invalidity thereof. 
 1.10 “Drug Approval Application” means,
with respect to a particular country, an application for regulatory approval required before commercial sale or commercial use of a Licensed Product in such country. 

1.11 “EU” means the European Union or any successor organization, including any of its member countries. 

1.12 “Field 1” means the diagnosis, prevention and treatment of disease in humans: (a) by the delivery of a Licensed
Product [***], or (b) by the delivery of a Licensed Product [***], (c) by targeting [***] except: [***]. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 1.13 “Field
2” means the diagnosis, prevention and treatment of disease in humans OTHER THAN: (a) by the delivery of a Licensed Product directly [***], or (b) by the delivery of a Licensed Product [***], or (c) by use of a Licensed
Product to target [***]. 
 1.14 “Fields” means Field 1 and Field 2. 

1.15 “First Commercial Sale” means, with respect to a particular Licensed Product in a given country, the first
arm’s-length commercial sale of such Licensed Product following Marketing Approval in such country by or under authority of Dicerna or any of its Affiliates, Sublicensees or distributors to a Third Party. 

1.16 “GAAP” means generally accepted accounting principles, consistently applied, as promulgated from time to time by the
Financial Accounting Standards Board. 
 1.17 “[***]” means [***]. 

1.18 “IND” means an “Investigational New Drug Application” as defined in 21 C.F.R. §312.3 that contains the
content, and is in the format, required by 21 C.F.R. §312.23, or a corresponding application with a regulatory agency in a country other than the United States, together with all additions, deletions, and supplements thereto. 

1.19 “License Year” means each calendar year during the term of this Agreement; except that the first License Year shall
commence on the Effective Date and end on December 31, 2007. 
 1.20 “Licensed Product” means a pharmaceutical product
(including, without limitation, kits, component sets or components thereof, regardless of concentration or formulation) that: [A] (i) is Covered by a Valid Claim, (ii) manufactured by a process or used in a method Covered by a Valid Claim,
or (iii) contains, as an active ingredient, any substance the manufacture, use, offer for sale or sale of which is Covered by a Valid Claim and [B] targets [***]. For the avoidance of doubt, a product otherwise meeting the criteria set forth in
[A](i), (ii) or (iii) above that targets a [***] and also targets [***] shall be considered a Licensed Product. For the purposes of the definition of Licensed Product, “targets” means possessing a degree of Watson-Crick base
pairing between the Licensed Product and either [***] or [***] that is sufficient to promote RNA induced silencing. By way of further clarification, “Licensed Product” shall include a product manufactured in a country in which such
manufacture is Covered by a Valid Claim and thereafter exported to and sold in a country in which no Valid Claim exists. 
 1.21
“Major Market” means any one of [***]. 
 1.22 “Marketing Approval” means all approvals, licenses,
registrations or authorizations of any federal, state or local regulatory agency, department, bureau or other governmental entity, necessary for the manufacturing, use, storage, import, transport, marketing and sale of Licensed Products in a country
or regulatory jurisdiction. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 1.23
“Marks” has the meaning set forth in Section 6.2. 
 1.24 “[***]” means [***]. 

1.25 “[***] Exclusive License” means a certain Exclusive License Agreement between COH and [***] dated [***]. 

1.26 “[***] Non-Exclusive License” means a certain Non-Exclusive License Agreement between COH and [***] dated [***]. 

1.27 “Net Sales” means [***]. 

1.28 “Patent Rights” means: (i) those issued United States patents and pending U.S. patent applications shown on
Schedule 1.28 attached hereto and foreign and international equivalents thereto, (ii) U.S., foreign and international patent applications and issued patents claiming inventions related to the subject matter disclosed in the patents and patent
applications shown on Schedule 1.28, which inventions were conceived and reduced to practice prior to the Effective Date, individually or jointly by Dr. John Rossi, Dr. Mark Behlke, or one or more individuals under the supervision of
either Dr. Rossi or Dr. Behlke, (iii) U.S., foreign and international patent applications and issued patents covering inventions made pursuant to a sponsored research, laboratory support or other agreement between Dicerna and COH
which agreement relates to the subject matter disclosed in patents and patent applications described in subsection (i) or (ii), above, (iv) U.S., foreign and international patent applications and issued patents covering inventions made
pursuant to a sponsored research, laboratory support or other agreement between Dicerna and [***] which agreement relates to the subject matter disclosed in patents and patent applications described in subsection (i) or (ii), above, to the
extent that COH Controls such patent applications and issued patents, (v) continuation and divisional applications and foreign equivalents that claim the same invention(s) and priority date as any of the foregoing,
(vi) continuation-in-part applications that repeat a substantial portion of any of the foregoing applications, (vii) Letters Patent or the equivalent issued on any of the foregoing applications throughout the world, and
(viii) amendments, extensions, renewals, reissues, and re-examinations of any of the foregoing. Notwithstanding the foregoing, “Patent Rights” shall not include any continuation-in-part application to the extent such application adds
new matter not contained in the earlier application to which the continuation-in-part application claims priority. 
 1.29
“Person” means any person or entity, including any individual, trustee, corporation, partnership, trust, unincorporated organization, limited liability company, business association, firm, joint venture or governmental agency or
authority. 
 1.30 “Phase 1 Clinical Trial” means, as to a specific Licensed Product, a study as described in 21 C.F.R.
§312.21(a) or a similar clinical study in a country other than the United States. 
 1.31 “Phase 2 Clinical Trial”
means, as to a specific Licensed Product, a study in humans designed with the principal purpose of determining initial efficacy and dosing of such Licensed Product in patients for the indication(s) being studied as described in 21 C.F.R.
§312.21(b); or a similar clinical study in a country other than the United States. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 1.32 “Phase
3 Clinical Trial” means, as to a specific Licensed Product, a lawful study in humans of the efficacy and safety of such Licensed Product, which is prospectively designed to demonstrate statistically whether such Licensed Product is
effective and safe for use in a particular indication in a manner sufficient to file an application to obtain Marketing Approval to market and sell that Licensed Product in the United States or another country for the indication being investigated
by the study, as described in 21 C.F.R. § 312.21(c); or similar clinical study in a country other than the United States. 
 1.33
“Qualified Financing” means the first sale of Dicerna Series A convertible preferred shares, either directly or through the issuance of convertible debt or both, alone or in conjunction with the sale of warrants, resulting in [***],
occurring on or before the sooner of: (i) March 31, 2008 and (ii) 180 days after the Effective Date. 
 1.34
“Sublicensee” means any Third Party which enters into an agreement with Dicerna involving the grant to such Third Party of any rights under the licenses granted to Dicerna under this Agreement. 

1.35 “Sublicense Revenues” means [***]. 

1.36 “Territory” means the entire world. 

1.37 “Third Party” means a Person that is not: (i) a Party to this Agreement or an Affiliate, or (ii) in the case
of Dicerna, a Sublicensee or distributor of a Licensed Product. 
 1.38 “United States” means the United States of America
and its territories and possessions as of the Effective Date, including the Commonwealth of Puerto Rico. 
 1.39 “Valid
Claim” means a claim of a pending patent application or an issued and unexpired patent included in the Patent Rights in a particular jurisdiction which claim has not, in such jurisdiction: (i) been finally rejected, or (ii) been
declared invalid or cancelled by the patent office or a court of competent jurisdiction in a decision that is no longer subject to appeal as a matter of right, or (iii) which claim is contained in a patent application or patent that has expired
or been abandoned. 
 ARTICLE 2: DEVELOPMENT AND COMMERCIALIZATION EFFORTS 

2.1 Development and Commercialization Responsibilities. Dicerna shall have the sole right and responsibility for, and control over, all
research, development, manufacturing and commercialization activities (including all regulatory activities) with respect to Licensed Products in the Fields. 

2.2 Dicerna Diligence. Dicerna shall use Commercially Reasonable Efforts to develop and commercialize Licensed Products in the Fields
in each of the Major Markets, directly or through one or more Affiliates or Sublicensees or distributors. Without limiting the foregoing, if Dicerna fails to accomplish any one of the “milestone events” set forth in this

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 
Section 2.2 (each a “Milestone Event”) by the date specified (each a “Deadline Date”), this Agreement shall terminate effective on [***] notice from COH to Dicerna to
such effect, without further right to cure. 
  

			
	 “Deadline Date”
	  	 “Milestone Event”

		
	1. The earlier of: (i) March 31, 2008. and (ii) 180 days after the Effective Date	  	Complete a Qualified Financing
		
	2. [***]	  	Enroll the first patient in the first Phase 1 Clinical Trial of a Licensed Product
		
	3. [***]	  	Enroll the first patient in the first Phase 2 Clinical Trial of a Licensed Product and enroll the first patient in the first Phase 1 Clinical Trial of a Licensed Product, which Licensed Product was not previously the subject of a
Phase 1 Clinical Trial
		
	4. [***]	  	Enroll the first patient in the first Phase 3 Clinical Trial of a Licensed Product

 Notwithstanding any other provision of this Agreement, Dicerna shall have the right to extend the Deadline Dates for Milestone
Events 2, 3 and 4, above, on one or more occasions, by not more than one year on each occasion, by payment to COH of $500,000. Upon the effective extension of any Deadline Date with respect to such a Milestone Event, such extension shall equally be
effective to extend the subsequent Deadline Dates for subsequent Milestone Events. By way of clarification, if Dicerna shall have effectively extended the second Deadline Date from [***] to [***], the third and fourth Deadline Dates shall be
extended, respectively, to [***] and [***]. In order for an extension to be effective as to any Milestone Event, such right shall have been exercised, and payment made, not less that [***] prior to the Deadline Date in question and shall not be
effective with respect to Milestone Events for which the Deadline Date has previously expired. If, however, Dicerna shall have extended the Deadline Dates but shall have achieved, before the applicable Deadline Date (disregarding such extension of
such Deadline Date), the first Milestone Event to have occurred after such extension, COH will refund to Dicerna the amount of the extension payment previously made by Dicerna. 

2.3 Governance. COH and Dicerna shall each designate one individual to serve as the main point of contact for communications related to
development and commercialization of Licensed Products under this Agreement (each a “Designated Representative”). The initial Designated Representative of COH shall be [***] and the initial Designated Representative of Dicerna shall be
James Jenson. Each Party may replace its Designated Representative at any time upon prior notice to the other Party. Dicerna shall keep COH reasonably informed as to progress in the development and commercialization of Licensed Products. Without
limiting the foregoing, on or before [***], Dicerna shall provide to COH a written report setting forth, in reasonable detail, its activities and achievements with respect to the development and commercialization of Licensed Products during the
preceding [***]. The Designated 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 
Representatives shall meet in person once each calendar year to present and discuss the current [***] at such location and date as mutually agreed. Each Party shall be responsible for all
expenses incurred by its Designated Representative in the participation in such annual meetings. 
 ARTICLE 3: LICENSE GRANTS 

3.1 Grant of Rights in the Fields. COH hereby grants to Dicerna: (i) an exclusive royalty-bearing right and license under the
Patent Rights to manufacture, use, offer for sale, sell and import Licensed Products in Field 1, in the Territory, and (ii) an exclusive royalty-bearing right and license under the Patent Rights, subject to such terms and conditions of the
[***] Non-Exclusive License as are applicable and in full force and effect, to manufacture, use, offer for sale, sell and import Licensed Products in Field 2, in the Territory; except that Dicerna’s rights in the Fields with respect to
diagnostic uses of Licensed Products are as set forth in Section 3.2, below. The foregoing grant of rights by COH to Dicerna shall be subject to the retained rights of the U.S. Government, if any, in the Patent Rights and to the royalty-free
right of City of Hope to practice the Patent Rights for educational, research and clinical uses. 
 3.2 Grant of Right for
Diagnostics. COH hereby grants to Dicerna an exclusive royalty-bearing right and license under the Patent Rights to manufacture, use, offer for sale, sell and import Licensed Products for human diagnostic uses in the Territory in the Fields
solely as expressly set forth in this Agreement. From time to time during the term of this Agreement, Dicerna shall have the right, on notice to COH, to nominate a specific Licensed Product for diagnostic uses, which Licensed Product shall, at the
time of such nomination, be currently the subject of a discovery or development program of Dicerna or a Sublicensee or approved for a therapeutic use in one of the Fields. If, at the time of nomination by Dicerna, rights to diagnostic uses of such
Licensed Product (i) have not previously been granted to a Third Party, or (ii) are not the subject of active negotiations between COH and a Third Party, Dicerna shall have an exclusive grant of rights to diagnostic uses of such Licensed
Product hereunder. Otherwise, Dicerna shall have no rights with respect to diagnostic uses of such Licensed Product. Following the nomination of a total of 20 specific Licensed Products pursuant to this Section 3.2, Dicerna’s right to
nominate further Licensed Products for diagnostic uses shall terminate and COH shall be free to exploit or dispose of diagnostic applications of Licensed Products not theretofore licensed to Dicerna as it sees fit. 

3.3 Right of First Negotiation. In the event that, during the term of this Agreement, the grant of license by COH to [***] set forth in
the [***] Exclusive License shall expire, lapse or otherwise terminate in whole or in part (such expiration, lapse or termination being referred to as a “[***] Termination”), COH shall promptly notify Dicerna. Such notice shall include
reasonable specificity as to the rights involved in such [***] Termination. Within [***] following Dicerna’s receipt of such notice, Dicerna shall notify COH whether Dicerna has an interest in securing for its own benefit the rights subject to
such [***] Termination. If Dicerna timely notifies COH to such effect, during the [***] period following such notice the Parties shall in good faith negotiate the terms and conditions under which the rights involved shall be exclusively licensed to
Dicerna. If Dicerna fails to timely notify COH, or if Dicerna so notifies COH but the Parties are unable to reach agreement during such [***] period, COH shall be free to exploit or dispose of the rights subject to such [***] Termination as it sees
fit. During such [***] period, COH shall not [***]. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 3.4 No Implied
Licenses. Dicerna acknowledges that the licenses granted in this Agreement are limited to the scope expressly granted and that, subject to the terms and conditions of this Agreement, all other rights under all Patent Rights and other
intellectual property rights Controlled by COH are expressly reserved to COH. Without limiting the foregoing, the Parties acknowledge that the grant of rights to Dicerna hereunder shall not include: (i) human diagnostics (except as expressly
provided in this Agreement), (ii) the diagnosis, prevention or treatment of disease in plants, (iii) veterinary applications, (iv) the alternation of agronomic characteristics or phenotypic properties in plants, (v) rights held
by [***] pursuant to the [***] Exclusive License or the [***] Non-Exclusive License (to the extent that such agreements are in full force and effect); and (vi) rights held by [***] pursuant to a certain [***]. 

3.5 Sublicensing. Each grant of license under this Agreement shall include the right to grant sublicenses, as provided herein. Dicerna
shall have the right to sublicense its rights hereunder to an Affiliate on notice to COH; provided, however, that such sub-license shall remain effective only so long as the sub-licensee Affiliate remains an Affiliate of Dicerna. Dicerna shall have
the right to sublicense its rights hereunder to a Third Party only with the prior written consent of COH, which consent shall not be unreasonably withheld or delayed. The terms and conditions of each sublicense of Dicerna’s rights hereunder
shall be consistent with this Agreement. A true and complete copy of each sublicense of Dicerna’s rights hereunder shall be delivered to COH promptly following the effective date of each such sublicense. [***]. 

3.6 COH Restriction. During the term of this Agreement, COH shall not grant to any Person any right or license to develop, manufacture, use,
offer to sell, sell or import Licensed Products in either or both of the Fields and in the Territory except, in the case of a [***] Termination, without first complying with Section 3.3, above, to the extent applicable. 

ARTICLE 4: PAYMENTS 
 4.1
Up-Front Payment. Dicerna shall pay to COH a one-time non-refundable license fee of $[***] within [***] after the Effective Date. 

4.2 Stock Grant. At the closing of the Qualified Financing, Dicerna shall issue to COH and such reasonable number of designees as COH
may specify which shall not exceed [***] in number (provided that, in the case of any such designee, such designee shall have demonstrated to the reasonable satisfaction of Dicerna that it is an “accredited investor” as such term is
defined in Regulation D under the Securities Act of 1933), the number of fully paid-up shares of Dicerna common stock [***]. COH and its designees shall enter into such investor rights and similar agreements as may be required of the founders or of
investors participating in the Qualified Financing. 
 4.3 License Maintenance Fee. For the first License Year, [***]. With respect
to each subsequent License Years, Dicerna shall pay to COH a license maintenance fee of $[***] on or before [***] of such License Year. Each such payment shall be credited against royalties otherwise due to COH pursuant to Section 4.5, below,
during the License Year in which payment was made but may not be carried over and credited in subsequent years. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 4.4 Milestone
Payments. Within [***] of the first occurrence of each “milestone achievement” set forth below, Dicerna shall pay COH or its designee the amount indicated below: 

 

					
	 Milestone Achievement
	  	Amount Due	 
		
	 [***]
	  	$	[***	] 
		
	 [***]
	  	$	[***	] 
		
	 [***]
	  	$	[***	] 
		
	 [***]
	  	$	[***	] 
		
	 [***]
	  	$	[***	] 

 4.5 Royalties. Dicerna shall pay to COH or its designee an amount equal to [***] percent of Net Sales.
Royalties shall be paid on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration in each country of the last to expire of the Patent Rights in such country Covering the manufacture, use, offer for sale or sale of
such Licensed Product. 
 4.6 Royalty Offsets. If [***] it is necessary to pay to a Third Party consideration (whether in the form of
a royalty or otherwise) for the right to make (or have made), use, sell, offer for sale or import a Licensed Product, Dicerna shall have the right with respect to any calendar quarter to set off [***] percent of the amount of any such consideration
payable with respect to such calendar quarter that, when added to the royalty payments otherwise payable hereunder with respect to such period, exceeds [***] percent of Net Sales of such Licensed Product in a given country for such calendar quarter
against [***] percent of the royalty payments otherwise payable under Section 4.5, above, with respect to such Licensed Product in such country during such calendar quarter; provided, however, that under no circumstances shall the royalties
payable to COH hereunder be less than [***] percent of Net Sales. 
 4.7 Sublicense Revenues. Except as provided below, Dicerna shall
pay to COH a percentage of Sublicense Revenues within [***] after payment is due from the relevant Sublicensee or distributor. If, on or before the [***] that such payment is due, Dicerna shall not have received such Sublicense Revenues, Dicerna
shall notify COH of such non-receipt, whereupon Dicerna and COH shall promptly consult as to the appropriate course of action to be taken with respect to the collection of such Sublicense Revenues. If, within [***] Dicerna and COH shall have agreed
upon and commenced the implementation of a course of action to accomplish such collection, [***]. If Dicerna and COH shall not be in agreement with respect to such course of action, [***]. Notwithstanding the foregoing, however, if Dicerna shall at
any time receive all or part of such Sublicense Revenues, Dicerna shall promptly pay the appropriate percentage thereof to COH. COH shall be entitled to [***] percent of all Sublicense Revenues 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 
derived from a grant of rights by Dicerna effective prior to the date on which Dicerna has expended $12.5 million in aggregate direct and indirect costs related to the development and
commercialization of Licensed Products. COH shall be entitled to [***] percent of all Sublicense Revenues derived from a grant of rights by Dicerna effective thereafter. In the case of a loan or other extension of credit that is other than an
arm’s-length credit relationship between an established financial institution and Dicerna, the proceeds of such loan shall be deemed to be Sublicense Revenues. In such case, Dicerna, upon receipt of any such loan proceeds, shall pay to COH the
percentage of such proceeds determined pursuant to the second and third sentences of this section, whereupon COH and Dicerna shall be subject to the following: (i) if and when Dicerna shall repay any such loan proceeds in cash, COH shall be
obligated to return to Dicerna the corresponding portion of such loan proceeds as shall be equal to the portion thereof used to determine the amount payable to COH hereunder, without interest; and (ii) such obligation on the part of COH to
return such portion shall not be effective until the [***] after having received notice from Dicerna of such payment on the part of Dicerna. 

4.8 Timing of Royalty Payments. Royalty payments due under Section 4.5, above, shall be paid annually within [***] following the
end of each License Year until the first License Year in which aggregate Net Sales reach $[***]. Thereafter, all royalty payments due under Section 4.5 shall be paid in quarterly installments, within [***] following the end of each calendar
quarter. 
 4.9 No Deductions from Payments. Except as expressly set forth in this Agreement, Dicerna is solely responsible for
payment of any fee, royalty or other payment due to any Third Party in connection with the research, development, manufacture, distribution, use, sale, import or export of a Licensed Product, and Dicerna shall not have the right to set off any
amounts paid to such Third Party, including fee, royalty or other payment, against any amount payable to COH hereunder. 
 4.10 Single
Royalty. Only a single royalty payment shall be due and payable on Net Sales of a Licensed Product, regardless if such Licensed Product is covered by more than one Valid Claim. 

4.11 Patent Expenses. COH represents and warrants that COH’s historic expenses incurred with respect to the prosecution and
maintenance of the Patent Rights through the dates specified on the invoices delivered to COH on or before [***], are as set forth in Schedule 4.11 attached hereto. Within [***] after the Effective Date, Dicerna shall pay to COH $[***], as
reimbursement of [***] of such historic expenses. Thereafter, Dicerna shall reimburse COH for the full amount of COH’s documented expenses reasonably incurred with respect to the prosecution and maintenance of the Patent Rights (including,
without limitation, expenses related to interference actions brought or defended with respect to the Patent Rights), less any portion of such expenses due to COH from [***], within [***] following presentation by COH to Dicerna of reasonable
documentation of such expenses. Within [***] after having received the same, COH will provide to Dicerna copies of all invoices for legal services for which COH intends to seek reimbursement hereunder, in form sufficient to reasonably disclose the
scope of services provided and the invoiced amount thereof; and COH will cooperate with Dicerna in resolving the amounts to be paid with respect to any such invoice the amount of which Dicerna shall judge to be unreasonable. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 ARTICLE 5:
REPORTS, AUDITS AND FINANCIAL TERMS 
 5.1 Royalty Reports. Within [***] after the end of each calendar quarter in which a
royalty payment under Article 4 is required to be made, Dicerna shall send to COH a report of Net Sales of the Licensed Products for which a royalty is due, which report sets forth for such calendar quarter the following information: (i) total
Net Sales of all Licensed Products sold in the Territory during such calendar quarter, (ii) Net Sales on a country-by-country basis, (iii) gross sales of Licensed Products on a country-by-country basis, (iv) quantity of Licensed
Products sold, (v) the exchange rate used to convert Net Sales from the currency in which they are earned to United States dollars; and (vi) the total royalty payments due. In addition, until such time as Dicerna has expended $[***] in
aggregate direct and indirect costs related to the development and commercialization of Licensed Products, within [***] after the end of each calendar quarter Dicerna shall send to COH a total of such direct and indirect costs through the end of
such quarter. 
 5.2 Additional Financial Terms. 

5.2.1 Currency. All payments to be made under this Agreement shall be made in United States dollars, unless expressly specified to the
contrary herein. Net Sales outside of the United States shall be first determined in the currency in which they are earned and shall then be converted into an amount in United States dollars. All currency conversions shall use the conversion rate
reported by Reuters, Ltd. on the last Business Day of the calendar quarter for which such payment is being determined. 
 5.2.2 Payment
Type. Amounts due under this Agreement shall be paid in immediately available funds, by means of wire transfer to an account identified by COH. 

5.2.3 Withholding of Taxes. Dicerna may withhold from payments due to COH amounts for payment of any withholding tax that is required
by law to be paid to any taxing authority with respect to such payments. Dicerna shall provide to COH all relevant documents and correspondence, and shall also provide to COH any other cooperation or assistance on a reasonable basis as may be
necessary to enable COH to claim exemption from such withholding taxes and to receive a full refund of such withholding tax or claim a foreign tax credit. Dicerna shall give COH proper evidence from time to time as to the payment of such tax. The
Parties shall cooperate with each other in seeking deductions under federal and state tax laws and any double taxation or other similar treaty or agreement from time to time in force. Such cooperation may include Dicerna making payments from a
single source in the U.S., where possible. 
 5.2.4 Late Payments. Any amounts not paid on or before the date due under this
Agreement are subject to interest from the date due through and including the date upon which payment is received. Interest is calculated, over the period between the date due and the date paid, at a rate equal to [***]. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 5.2.5 Blocked
Currency. If, at any time, legal restrictions prevent the prompt remittance of part or all royalties with respect to any country where a Licensed Product is sold, payment shall be made through such lawful means or methods as Dicerna may
determine. When in any country, the law or regulations prohibit both the transmittal and deposit of royalties or other payments, Dicerna shall continue to report all such amounts, but may suspend payment for as long as such prohibition is in effect.
As soon as such prohibition ceases to be in effect, all amounts that would have been obligated to be transmitted or deposited but for the prohibition, together with accrued interested thereon, shall promptly be transmitted to COH. 

5.3 Accounts and Audit. 

5.3.1 Records. Dicerna shall keep, and shall require that each Sublicensee keep, full, true and accurate books of account containing
the particulars of its Net Sales and the calculation of royalties, as well as, in the case of Dicerna, the expenditures by Dicerna pursuant to Section 4.6, above. Dicerna and its Sublicensees shall each keep such books of account and the
supporting data and other records at its principal place of business. Such books and records must be maintained available for examination in accordance with this Section 5.3.1 for [***] after the end of the calendar year to which they pertain,
and otherwise as reasonably required to comply with GAAP. 
 5.3.2 Appointment of Auditor. COH may appoint an
internationally-recognized independent accounting firm reasonably acceptable to Dicerna to inspect the relevant books of account of Dicerna and its Sublicensee to verify any reports or statements provided, or amounts paid or invoiced (as
appropriate), by Dicerna or its Sublicensees. 
 5.3.3 Procedures for Audit. COH may exercise its right to have Dicerna’s and
its Sublicensee’s relevant records examined only during the [***] period during which Dicerna is required to maintain records, no more than [***] in any [***]. Dicerna and its Sublicensees are required to make records available for inspection
only during regular business hours, only at such place or places where such records are customarily kept, and only upon receipt of at least [***] advance notice from COH. 

5.3.4 Audit Report. The independent accountant will be instructed to provide to COH an audit report containing its conclusions
regarding the audit, and specifying whether the amounts paid were correct, and, if incorrect, the amount of any underpayment or overpayment. 

5.3.5 Underpayment and Overpayment. After review of the auditor’s report: (i) if there is an uncontested underpayment by
Dicerna for all of the periods covered by such auditor’s report, then Dicerna shall pay to COH the full amount of that uncontested underpayment, and (ii) if there is an uncontested overpayment for such periods, then COH shall provide to
Dicerna a credit against future payments (such credit equal to the full amount of that overpayment), or, if Dicerna is not obligated to make any future payments, then COH shall pay to Dicerna the full amount of that overpayment. Contested amounts
are subject to dispute resolution under Article 11. If the total amount of any such underpayment (as agreed to by Dicerna or as determined under Article 11) exceeds [***] percent of the amount previously paid by Dicerna for the period subject to
audit, then Dicerna shall pay the reasonable costs for the audit. Otherwise, all costs of the audit shall be paid by COH. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 ARTICLE 6:
INTELLECTUAL PROPERTY; PATENT PROSECUTION, MAINTENANCE AND ENFORCEMENT. 
 6.1 Patent Prosecution, Maintenance and Enforcement.
(a) COH shall be solely responsible, at its sole discretion and expense, for the prosecution and maintenance of the Patent Rights, using either its current patent counsel or alternative patent counsel [***]. COH shall use reasonable efforts to
afford Dicerna with the opportunity to provide meaningful input to COH and its patent counsel with respect to the prosecution, maintenance, assertion and defense of the Patent Rights if the same would be reasonably likely to implicate the Patent
Rights within the Fields. Without limiting the foregoing, COH, directly or through its counsel, shall: (i) promptly provide to Dicerna copies of all correspondence between COH and the U.S. Patent and Trademark Office and its foreign
counterparts with respect to the Patent Rights, (ii) provide Dicerna with advance copies of all proposed submissions to any patent office and reasonable opportunity to provide comments to COH with respect thereto, (iii) promptly notify
Dicerna of any material event related to the enforceability of the Patent Rights (including, without limitation, the issuance or rejection thereof by the US Patent & Trademark Office and its foreign counterparts), (iv) provide Dicerna
with a [***] written update on the filing and prosecution status of the Patent Rights, and (v) to the extent consistent with the preservation of privilege, afford Dicerna’s patent counsel the opportunity to consult directly with COH’s
patent counsel with respect to the prosecution, maintenance and enforcement of the Patent Rights. 
 (b) On or before (i) [***]
following the Effective Date, and (ii) [***] after the filing of each patent application included in the Patent Rights which is not pending as of the Effective Date, COH shall notify Dicerna of COH’s then-current intentions regarding the
jurisdictions in which COH expects to file counterpart applications regarding any then existing Patent Rights. Promptly following such notice the Parties shall consult in good faith regarding the jurisdictions in which such counterpart applications
should in fact be filed. If Dicerna shall reject the filing of a counterpart in any jurisdiction recommended by COH, Dicerna shall thereafter have no responsibility for the costs associated with such filing in such jurisdiction and such Patent
Rights in such jurisdiction shall no longer be considered “Patent Rights.” If COH declines to file and thereafter diligently prosecute counterpart applications in any jurisdiction, Dicerna shall have the right to do so at its sole expense,
in consultation with COH, using counsel of Dicerna’s choosing. 
 (c) Each Party shall promptly notify the other in the event it
becomes aware of any actual or probable infringement of any of the Patent Right in or relevant to the Field or of any Third Party claim regarding the enforceability or validity of any Patent Rights. As between the Parties, COH may, following
consultation with Dicerna, in its sole discretion and at its sole expense, take action against any alleged infringer or in defense of such any Third Party claim. Any recovery obtained by COH as the result of legal proceedings initiated and paid for
by COH pursuant to this subsection (b) shall be for the sole benefit of COH. 
 (d) In the event that: (i) COH declines either to
cause such infringement to cease (e.g. by settlement or injunction) or to initiate and thereafter diligently maintain legal proceedings against the infringer, and (ii) [***]. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 6.2
Trademarks. Dicerna shall be responsible for the selection, registration, maintenance, and defense of all trademarks for use in connection with the sale or marketing of Licensed Products in the Field in the Territory (the “Marks”),
as well as all expenses associated therewith. All uses of the Marks by Dicerna or a Sublicensee shall comply in all material respects with all applicable laws and regulations (including those laws and regulations particularly applying to the proper
use and designation of trademarks in the applicable countries). Dicerna shall not, without COH’s prior written consent, use any trademarks or house marks of COH (including the COH corporate name), or marks confusingly similar thereto, in
connection with Dicerna commercialization of Licensed Products under this Agreement. Dicerna shall own all Marks. 
 6.3 Challenge to the
Patent Rights by Dicerna. 
 (a) The Parties acknowledge and agree that they are entering the Agreement in lieu of enforcing their
respective patent rights, defenses and remedies concerning the Patent Rights under relevant laws, including without limitation under 35 U.S.C. 100-376 et seq. By entering the Agreement each Party waives its Patent Rights in favor of proceeding under
the terms of the Agreement. Each Party further acknowledges that each and every term in the Agreement, including but not limited to the fees, milestone payments and the royalties set forth in Article 4 herein, reflects the value of avoiding the risk
and uncertainty associated with litigating the Patent Rights and the risk of being subject to certain rights, defenses and/or remedies. 

(b) The Parties acknowledge and agree that COH may terminate the Agreement at COH’s sole and absolute discretion, in the event Dicerna or
any of its Affiliates or Sublicensees challenges, directly or indirectly, the validity, enforceability and/or scope of any claim within the Patent Rights in a court or patent office or other governmental agency. In the event of termination by COH
pursuant to this Section 6.3(b), any fees, milestone payments and/or royalties or other payment owed to COH prior to such termination shall become payable and shall be non-refundable. 

(c) The Parties further agree that in the event Dicerna or any of its Affiliates or Sublicensees directly or indirectly files a lawsuit or
other proceeding to challenge the validity, enforceability and/or scope of any claim within the Patent Rights in a court or patent office or other governmental agency, and thereby obtains a final non-appealable judgment upholding the validity and
enforceability of the challenged Patent Rights and finding at least one claim of such Patent Rights to be infringed by Dicerna or any one of its Affiliates or Sublicensees, Dicerna shall: (i) reimburse COH all of its attorneys’ fees and
expenses expended in connection with defending such lawsuit or other proceeding, and (ii) pay to COH modified fees for the period commencing on the filing date of such lawsuit or proceeding and thereafter during the Term; such modified fees
shall be [***], and shall constitute additional consideration to COH for Dicerna’s (or Affiliates’ or Sublicensees’) decision to exercise the Patent Rights notwithstanding the Agreement. 

ARTICLE 7: TERM AND TERMINATION 

7.1 Term. The term of this Agreement (the “Term”) shall commence on the Effective Date. Notwithstanding any other provision
of this Agreement, unless sooner terminated by 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 
mutual agreement or pursuant to any other provision of this Agreement, all obligations under this Agreement shall terminate on the date on which all obligations under this Agreement between the
Parties with respect to the payment of milestones or royalties with respect to Licensed Products have terminated or expired. 
 7.2
Termination. 
 7.2.1 Material Breach. Either Party may terminate this Agreement for any material breach by the other Party,
provided that the terminating Party shall have given the breaching Party written notice of such breach, the Party receiving notice of breach shall have failed to cure that breach within [***], and the Party originally delivering the notice of
breach shall have delivered written notice of termination within [***] after the end of such [***] period. Notwithstanding the foregoing, if the allegedly breaching Party shall in good faith dispute such allegation of material breach or shall
dispute its alleged failure to cure or remedy such material breach and provides written notice of that dispute to the other Party within the above time periods, then the matter will be addressed under the dispute resolution provisions in Article 11,
and the notifying Party may not terminate this Agreement until it has been determined under Article 11 that: (i) the allegedly breaching Party was in material breach of this Agreement at the times stated, and (ii) that timely cure of such
material breach did not occur (the termination of an action that constitutes a breach within the time prescribed shall be deemed a cure). 

7.2.2 Bankruptcy. COH shall have the right to terminate this Agreement upon written notice to Dicerna, in the event that Dicerna seeks
protection of any bankruptcy or insolvency law, a proceeding in bankruptcy or insolvency is filed by or against Dicerna, or there is adjudication by a court of competent jurisdiction that Dicerna is bankrupt or insolvent. 

7.2.3 Termination at Will by Dicerna. Dicerna shall have the right to terminate this Agreement upon written notice to COH without
cause, effective [***] following the date of such notice. 
 7.3 Effect of Termination or Expiration. 

7.3.1 Upon any termination of this Agreement all rights and licenses granted to Dicerna under Article 4 shall immediately terminate, except
that Dicerna shall have the right to continue to sell Licensed Products manufactured prior to the effective date of such termination until [***]. 

7.3.2 Upon termination of this Agreement 

(a) Each Party shall promptly return to the other Party all relevant records and materials in its possession or control containing or
comprising the other Party’s Confidential Information and to which the Party does not retain rights hereunder. 
 (b) [***]. 

(c) Dicerna shall discontinue making any representation regarding its status as a licensee of COH for Licensed Products. Subject to
Section 7.3.1, above, Dicerna shall cease conducting any activities with respect to the marketing, promotion, sale or distribution of Licensed Products. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 7.3.3 Termination or
expiration of this Agreement, through any means and for any reason, shall not relieve the Parties of any obligation accruing prior thereto, including the payment of all sums due and payable, and shall be without prejudice to the rights and remedies
of either Party with respect to any antecedent breach of any of the provisions of this Agreement. 
 7.4 Survival. In addition to as
set forth in Section 7.3 and otherwise explicitly set forth in this Agreement, Sections 9.5 and 9.6 shall survive expiration or termination of this Agreement for any reason. 

ARTICLE 8: REPRESENTATIONS AND WARRANTIES 

8.1 Mutual Representations and Warranties. COH and Dicerna each represents and warrants as follows: 

8.1.1 It has the right and authority to enter into this Agreement; 

8.1.2 It has been informed of its right to consult an attorney, has consulted with an attorney of its choice, and has read this Agreement,
with assistance from its counsel of choice. It understands all of this Agreement’s terms. It has been given a reasonable amount of time to consider the contents of this Agreement before each Party executed it. It agrees that it is executing
this Agreement voluntarily with full knowledge of this Agreement’s legal significance; and 
 8.1.3 It has made such investigation of
all matters pertaining to this Agreement that it deems necessary, and does not rely on any statement, promise, or representation, whether oral or written, with respect to such matters other than those expressly set forth herein. It agrees that it is
not relying in any manner on any statement, promise, representation or understanding, whether oral, written or implied, made by any person or entity, not specifically set forth in this Agreement. It acknowledges that, after execution of this
Agreement, it may discover facts different from or in addition to those which it now knows or believes to be true. Nevertheless, it agrees that this Agreement shall be and remain in full force and effect in all respects, notwithstanding such
different or additional facts. 
 8.2 Exclusions. Nothing in this Agreement is or shall be construed as: 

8.2.1 A warranty or representation by COH as to the validity or scope of any claim or patent or patent application within the Patent Rights;

 8.2.2 A warranty or representation by COH that anything made, used, sold, or otherwise disposed of under any license granted in this
Agreement is or will be free from infringement of any patent rights or other intellectual property right of any Third Party; 
 8.2.3 A
grant by COH, whether by implication, estoppel, or otherwise, of any licenses or rights other than that expressly granted under this Agreement; 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 8.2.4 An obligation
on COH to bring or prosecute any suit or action against a third party for infringement of any of the Patent Rights. 
 8.3 COH
Representations. COH hereby represents, warrants and covenants to Dicerna that it has not, prior to the Effective Date, entered into any agreement and has not granted any now existing, or agreed to grant any future, license, right or privilege
which agreement, license, right or privilege conflicts in any way with any license, right or privileges granted to Dicerna hereunder. 

8.3.1 Accredited Investor. It is an “accredited investor” as such term is defined in Regulation D under the Securities Act of
1933, as amended. 
 8.3.2 Power. It has the full right, power and authority, and has obtained all approvals, permits or consents
necessary, to enter into this Agreement and to perform all of its obligations hereunder and to grant the licenses provided hereunder. 

8.3.3 Prior Filings. It has not, prior to the date of the execution and delivery of this Agreement, filed any patent application for
any invention claiming subject matter that includes any subject matter claimed in any patent application or patent specifically identified in Schedule 1.28 except the patent applications described in Schedule 8.3.4. 

8.3.4 Invention Disclosure. It is not, prior to the date of the execution and delivery of this Agreement, in receipt of any invention
disclosure regarding any subject matter described in any patent application listed in Schedule 1.28 from any person who is obligated to assign his or her inventions to COH except for such invention disclosures that are subsumed by the patent
applications or patents specifically identified in Schedule 1.28 or Schedule 8.3.4. 
 8.3.5 True Copies. The copies of the [***]
Exclusive License, the [***] Non-Exclusive License and the [***] provided to Dicerna by COH are true copies, subject only to the redactions obvious from the face of the copies provided. 

8.4 Dicerna Representations. Dicerna hereby represents and warrants to COH that Dicerna has not, prior to the Effective Date, entered
into any agreement that conflicts in any way with this Agreement or Dicerna’s obligations hereunder. 
 8.5 DISCLAIMER. NO
WARRANTY IS GIVEN WITH RESPECT TO THE PATENT RIGHTS, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND THE PARTIES SPECIFICALLY DISCLAIM ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, VALIDITY OF THE PATENT RIGHTS OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY OR OTHER RIGHTS OF ANY THIRD PARTY. THE WARRANTIES SET FORTH IN SECTIONS 8.1, 8.3 AND 8.4 ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, VALIDITY, NON-INFRINGEMENT AND ALL SUCH OTHER WARRANTIES ARE HEREBY EXPRESSLY DISCLAIMED. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 ARTICLE 9:
INDEMNIFICATION 
 9.1 Indemnification by Dicerna. Dicerna shall defend, indemnify and hold harmless COH and its officers,
directors, shareholders, employees and agents from and against any and all Third Party liabilities, claims, suits, and expenses, including reasonable attorneys’ fees (collectively, “Losses”), arising out of or in any way attributable
to (i) the inaccuracy or breach of any representation or warranty made by Dicerna under this Agreement, (ii) the research, development, marketing, approval, manufacture, packaging, labeling, handling, storage, transportation, use,
distribution, promotion, marketing or sale of Licensed Products by or on behalf of Dicerna, or (iii) the negligence, willful misconduct or failure to comply with applicable law of Dicerna or any of its Affiliates or Sublicensees, or their
respective officers, directors, employees or agents; in each case except to the extent that such Losses are attributable to (a) COH’s breach of any representation or warranty made by COH under this Agreement, (b) COH’s breach of
its obligations under this Agreement, and/or (c) the negligence or willful misconduct of COH or its officers, directors or employees acting within the scope of their authority on behalf of COH. 

9.2 Indemnification by COH. COH shall defend, indemnify and hold harmless Dicerna and its Affiliates and their respective officers,
directors, employees and agents from and against any and all Losses arising out of or in any way attributable to (i) the inaccuracy or breach of any representation or warranty made by COH under this Agreement, or (ii) the negligence or
willful misconduct of COH or any of its Affiliates, or their respective officers, directors or employees; in each case except to the extent that such Losses are attributable to: (a) Dicerna’s breach of any representation or warranty made
by Dicerna under this Agreement, (b) Dicerna’s breach of its obligations under this Agreement, and/or (c) the negligence or willful misconduct of Dicerna or any of its Affiliates or Sublicensees or their respective officers,
directors, employees or agents. 
 9.3 Procedure. The indemnities set forth in this Article 9 are subject to the condition that the
Party seeking the indemnity shall forthwith notify the indemnifying Party on being notified or otherwise made aware of a liability, claim, suit, action or expense and that the indemnifying Party defend and control any proceedings with the other
Party being permitted to participate at its own expense (unless there shall be a conflict of interest which would prevent representation by joint counsel, in which event the indemnifying Party shall pay for the other Party’s counsel);
provided, that, the indemnifying Party may not settle the liability, claim, suit, action or expense, or otherwise admit fault of the other Party or consent to any judgment, without the written consent of the other Party (such consent
not to be unreasonably withheld). Notwithstanding the foregoing, no delay in the notification of the existence of any claim of Loss shall cause a failure to comply with this Section 9.3 as long as such delay shall not have materially impaired
the rights of the Indemnifying Party. 
 9.4 Insurance. Commencing as of the date Dicerna files an IND for a Licensed Product, and
thereafter for the period of time required under this Section 9.4, Dicerna shall obtain and maintain on an ongoing basis, Products Liability insurance, including contractual liability, in the minimum amount of $[***] per occurrence, combined
single limit for bodily injury and property damage liability and naming COH as an additional insured by endorsement. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 
All such insurance coverage shall be in a combination of primary and additional insurance, with the primary insurance to be not less than $[***] in amount, with respect to Dicerna’s own
participation under this Agreement, and shall be maintained with an insurance company or companies having an A.M. Best’s rating (or its equivalent) of A-XII or better. The insurance policies shall be under an occurrence form, but if only a
claims-made form is reasonably available to Dicerna, then in such a case, Dicerna shall maintain the insurance coverage for at least [***] following completing performance of its obligations under this Agreement. Dicerna shall provide to COH its
certificates of insurance evidencing the insurance coverage set forth in this Section 9.4. Dicerna shall provide to COH at least [***] prior written notice of any cancellation, nonrenewal or material change in any of the insurance coverage.
Dicerna shall, upon receipt of written request from COH, provide renewal certificates to COH for as long as Dicerna is required to maintain insurance coverage hereunder. 

9.5 LIMITATION ON DAMAGES. NOTWITHSTANDING ANYTHING CONTAINED IN THIS AGREEMENT TO THE CONTRARY: (i) IN NO EVENT SHALLEITHER PARTY
BE LIABLE TO THE OTHER FOR [***] WHETHER BASED UPON BREACH OF WARRANTY, BREACH OF CONTRACT, NEGLIGENCE, STRICT TORT OR ANY OTHER LEGAL THEORY, and (ii) IN NO EVENT SHALL COH BE LIABLE TO DICERNA FOR [***]. Clause (i) of the foregoing
sentence shall not limit the obligation of Dicerna under Section 9.1 to indemnify COH for indirect, incidental, consequential or punitive damages awarded against COH. 

9.6 Sole Remedy. [***]. 

ARTICLE 10: CONFIDENTIALITY 

10.1 Confidential Information. During the Term and for [***] thereafter without regard to the means of termination: (i) COH shall
not use, for any purpose other than the purpose of this Agreement, or reveal or disclose to any Third Party Dicerna Confidential Information; and (ii) Dicerna shall not use, for any purpose other than the purpose of this Agreement, or reveal or
disclose to any Third Party COH Confidential Information. The Parties shall take reasonable measures to assure that no unauthorized use or disclosure is made by others to whom access to such information is granted. 

10.2 Exceptions. Notwithstanding the foregoing, a Party may use and disclose Confidential Information of the other Party as follows:

 (a) if required by applicable law, rule, regulation, government requirement and/or court order, provided, that, the
disclosing Party promptly notifies the other Party of its notice of any such requirement and provides the other Party a reasonable opportunity to seek a protective order or other appropriate remedy and/or to waive compliance with the provisions of
this Agreement; 
 (b) to the extent such use and disclosure occurs in the filing or publication of any patent application or patent on
inventions; 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 (c) as necessary or
desirable for securing any regulatory approvals, including pricing approvals, for any Licensed Products, provided, that, the disclosing Party shall take all reasonable steps to limit disclosure of the Confidential Information outside
such regulatory agency and to otherwise maintain the confidentiality of the Confidential Information; 
 (d) to take any lawful action that
it deems necessary to protect its interest under, or to enforce compliance with the terms and conditions of, this Agreement; 
 (e) to the
extent necessary, to its Affiliates, directors, officers, employees, consultants, vendors and clinicians under written agreements of confidentiality at least as restrictive as those set forth in this Agreement, who have a need to know such
information in connection with such Party performing its obligations or exercising its rights under this Agreement; and 
 (f) by Dicerna,
to actual and potential investors, licensees and commercial collaborators, under written agreements of confidentiality at least as restrictive as those set forth in this Agreement. 

10.3 Certain Obligations. During the Term and for a period of [***] thereafter and subject to the exceptions set forth in
Section 10.2, Dicerna, with respect to COH Confidential Information, and COH, with respect to Dicerna Confidential Information, agree: 

(a) to use such Confidential Information only for the purposes contemplated under this Agreement, 

(b) to treat such Confidential Information as it would its own proprietary information which in no event shall be less than a reasonable
standard of care, 
 (c) to take reasonable precautions to prevent the disclosure of such Confidential Information to a Third Party without
written consent of the other Party, and 
 (d) to only disclose such Confidential Information to those employees, agents and Third Party
contractors who have a need to know such Confidential Information for the purposes set forth herein and who are subject to obligations of confidentiality no less restrictive than those set forth herein. 

10.4 Disclosures and Public Announcements. During the period from the Effective Date through the date that is 90 days following the
closing of a Qualified Financing, neither Party shall issue any press release or other publicity materials, or make any public presentation with respect to the existence of, or any of the terms or conditions of, this Agreement or the programs or
efforts being conducted by the other Party hereunder, in each case without the prior written consent of such Party. Thereafter, the Parties will consult with each other prior to the release of any public announcement or other publicity materials.
The foregoing restriction shall not apply to: 
 (a) disclosures to a Party’s attorneys, advisors or investors on a need to know basis
under circumstances that reasonably ensure the confidentiality thereof, and 
 (b) any future disclosures required by law or regulation,
including as may be required in connection with any filings made with, or by the disclosure policies of a major stock exchange, provided that the disclosing Party (i) use all reasonable efforts to inform the other Party prior to
making any such disclosures and cooperate with the other Party in seeking a protective order or other appropriate remedy (including redaction) and (ii) whenever possible, request confidential treatment of such information. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 10.5
Termination. Upon termination, but not expiration, of this Agreement and upon the request of the disclosing Party, the receiving Party shall promptly return to the disclosing Party or destroy all copies of Confidential Information received
from such Party, and shall return or destroy, and document the destruction of, all summaries, abstracts, extracts, or other documents which contain any Confidential Information of the other Party in any form, except that each Party shall be
permitted to retain a copy (or copies, as necessary) of such Confidential Information for archival purposes or as required by any law or regulation. 

ARTICLE 11: DISPUTE RESOLUTION 
 All
Disputes shall be first referred to a Senior Vice President of COH (the “COH SVP”) and the Senior Vice President, Business Development, or equivalent, of Dicerna (the “Dicerna SVP”) of Dicerna for resolution, prior to proceeding
under the other provisions of this Article 11. A Dispute shall be referred to such executives upon one Party (the “Initiating Party”) providing the other Party (the “Responding Party”) with written notice that such Dispute
exists, together with a written statement describing the Dispute with reasonable specificity and proposing a resolution to such Dispute that the Initiating Party is willing to accept, if any. Within [***] after having received such statement and
proposed resolution, if any, the Responding Party shall respond with a written statement that provides additional information, if any, regarding such Dispute, and proposes a resolution to such Dispute that the Responding Party is willing to accept,
if any. In the event that such Dispute is not resolved within [***] of the Responding Party’s receipt of the Initiating Party’s written notice, either Party may bring and thereafter maintain suit against the other with respect to such
Dispute; provided, however, that the exclusive jurisdiction of any such suit shall be the state and federal courts located in Los Angeles County, California, and the Parties hereby consent to the exclusive jurisdiction and venue of such courts. 

ARTICLE 12: MISCELLANEOUS 

12.1 Assignment and Delegation. Except as expressly provided in this Section 12.1, neither this Agreement nor any right or
obligation hereunder [***]. Notwithstanding the foregoing, [***]. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the Parties hereto and their respective successors and permitted assignees. Any transfer or
assignment of this Agreement in violation of this Section 12.1 shall be null and void. 
 12.2 Entire Agreement. This Agreement
contains the entire agreement between the Parties relating to the subject matter hereof, and all prior understandings, representations and warranties between the Parties are superseded by this Agreement. 

12.3 Amendments. Changes and additional provisions to this Agreement shall be binding on the Parties only if agreed upon in writing and
signed by the Parties. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 12.4 Applicable
Law. This Agreement shall be construed and interpreted in accordance with the laws of the State of California and all rights and remedies shall be governed by such laws without regard to principles of conflicts of law. 

12.5 Force Majeure. If the performance of this Agreement or any obligations hereunder is prevented, restricted or interfered with by
reason of earthquake, fire, flood or other casualty or due to strikes, riot, storms, explosions, acts of God, war, or a similar occurrence or condition beyond the reasonable control of the Parties, the Party so affected shall, upon giving prompt
notice to the other Parties, be excused from such performance during such prevention, restriction or interference, and any failure or delay resulting therefrom shall not be considered a breach of this Agreement. 

12.6 Severability. The Parties do not intend to violate any public policy or statutory common law. However, if any sentence, paragraph,
clause or combination of this Agreement is in violation of any law or is found to be otherwise unenforceable, such sentence, paragraph, clause or combination of the same shall be deleted and the remainder of this Agreement shall remain binding,
provided that such deletion does not alter the basic purpose and structure of this Agreement. 
 12.7 Notices. All
notices, requests, demands, and other communications relating to this Agreement shall be in writing in the English language and shall be delivered in person or by mail, international courier or facsimile transmission (with a confirmation copy
forwarded by courier or mail). Notices sent by mail shall be sent by first class mail or the equivalent, registered or certified, postage prepaid, and shall be deemed to have been given on the date actually received. Notices sent by international
courier shall be sent using a service which provides traceability of packages. Notices shall be sent as follows: 
  

					
		 	Notices to COH:	    	with a copy to:
			
		 	Office of Technology Licensing	    	Office of General Counsel
		 	City of Hope	    	City of Hope
		 	1500 East Duarte Road.	    	1500 East Duarte Road
		 	Duarte, CA 91010	    	Duarte CA 91010
			
		 	Attn: Sr. VP, Applied Technology	    	Attn: General Counsel
		 	Development	    	
		 		    	Fax: [***]
		 	Fax: [***]	    	

  

					
		 	Notices to Dicerna:	    	with a copy to:
			
		 	Dicerna Pharmaceuticals, Inc.	    	
		 	14 Peterson Circle	    	Burns & Levinson LLP
		 	Sudbury, MA 01776	    	125 Summer Street
		 		    	Boston, MA 02110
		 	Attn: Chief Executive Officer	    	
		 		    	Attention: James H. Belanger, Esq.
		 	Facsimile: [***]	    	
		 		    	Facsimile: 617-345-3299

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 Either Party may change its address
for notices or facsimile number at any time by sending written notice to the other Party. 
 12.8 Independent Contractor. Nothing
herein shall create any association, partnership, joint venture, fiduciary duty or the relation of principal and agent between the Parties hereto, it being understood that each Party is acting as an independent contractor, and neither Party shall
have the authority to bind the other or the other’s representatives in any way. 
 12.9 Waiver. No delay on the part of either
Party hereto in exercising any power or right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any power or right hereunder preclude other or further exercise thereof or the exercise of any other power or
right. No waiver of this Agreement or any provision hereof shall be enforceable against any Party hereto unless in writing, signed by the Party against whom such waiver is claimed, and shall be limited solely to the one event. 

12.10 Interpretation. This Agreement has been prepared jointly and no rule of strict construction shall be applied against either
Party. In this Agreement, the singular shall include the plural and vice versa and the word “including” shall be deemed to be followed by the phrase “without limitation.” The section headings contained in this Agreement are
inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement. 
 12.11 Counterparts.
This Agreement may be executed in counterparts, each of which together shall constitute one and the same Agreement. For purposes of executing this agreement, a facsimile copy of this Agreement, including the signature pages, will be deemed an
original. 
 12.12 Dicerna Covenant. Dicerna covenants and agrees that, in conducting activities contemplated under this Agreement,
it shall comply in all material respects with all applicable laws and regulations including, without limitation, those related to the manufacture, use, labeling importation and marketing of Licensed Products. 

12.13 Dicerna Certification. Dicerna hereby certifies to COH under penalty of perjury, that neither Dicerna nor any of its current
officers, directors or shareholders has been convicted of a criminal offense related to health care and is not currently debarred, excluded or otherwise ineligible for participation in federally funded health care programs. Throughout the term of
this Agreement Dicerna shall: (i) notify COH in writing immediately of any threatened, proposed or actual conviction relating to health care, or any threatened, proposed or actual debarment or exclusion from participation in federally funded
health care programs, of Dicerna or any officer or director of Dicerna, and (ii) refrain from knowingly employing or contracting with individuals or entities excluded from participation in a federally funded health care program. Any material
breach of this Section 12.12 by Dicerna shall be grounds for immediate termination of this Agreement by COH. 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

*    *    *    *    * 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  
 IN WITNESS WHEREOF,
the Parties have executed this Agreement by their duly authorized representative. 
  

									
	DICERNA THERAPEUTICS, INC.	 		 	CITY OF HOPE
					
	By:	 	 /s/ James Jenson
	 		 	By:	 	 [***]

	Name:	 	James Jenson	 		 	Name:	 	[***]
					
	Title:	 	President & Chief Executive Officer	 		 	Title:	 	[***]
					
		 		 		 	By:	 	[***]
					
		 		 		 	Name:	 	[***]
					
		 		 		 	Title:	 	[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]